OA16302A - 6-Cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors. - Google Patents
6-Cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors. Download PDFInfo
- Publication number
- OA16302A OA16302A OA1201300022 OA16302A OA 16302 A OA16302 A OA 16302A OA 1201300022 OA1201300022 OA 1201300022 OA 16302 A OA16302 A OA 16302A
- Authority
- OA
- OAPI
- Prior art keywords
- group
- substituents
- fluorine
- substituted
- another
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 34
- 102100005348 PDE9A Human genes 0.000 title description 29
- 101700037958 PDE9A Proteins 0.000 title description 29
- 239000003112 inhibitor Substances 0.000 title description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 212
- 125000001424 substituent group Chemical group 0.000 claims abstract description 122
- 201000010099 disease Diseases 0.000 claims abstract description 62
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 33
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 30
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 29
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims abstract description 28
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims abstract description 26
- 206010057668 Cognitive disease Diseases 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims abstract description 13
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 13
- 206010001897 Alzheimer's disease Diseases 0.000 claims abstract description 11
- 125000003118 aryl group Chemical group 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 158
- 229910052731 fluorine Inorganic materials 0.000 claims description 75
- 239000011737 fluorine Substances 0.000 claims description 74
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 73
- 239000011780 sodium chloride Substances 0.000 claims description 70
- 150000003839 salts Chemical class 0.000 claims description 69
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 55
- -1 tetrahydropyranyl 2- Chemical group 0.000 claims description 50
- 239000000460 chlorine Substances 0.000 claims description 29
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 25
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 25
- 229910052801 chlorine Inorganic materials 0.000 claims description 25
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 25
- 125000004076 pyridyl group Chemical group 0.000 claims description 21
- 206010012289 Dementia Diseases 0.000 claims description 20
- 125000004429 atoms Chemical group 0.000 claims description 18
- 230000015654 memory Effects 0.000 claims description 15
- 230000001225 therapeutic Effects 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 11
- 125000005842 heteroatoms Chemical group 0.000 claims description 11
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 9
- 125000002971 oxazolyl group Chemical group 0.000 claims description 9
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 9
- 125000000335 thiazolyl group Chemical group 0.000 claims description 9
- 210000004556 Brain Anatomy 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 206010004938 Bipolar disease Diseases 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 206010013496 Disturbance in attention Diseases 0.000 claims description 5
- 210000004072 Lung Anatomy 0.000 claims description 5
- 210000000952 Spleen Anatomy 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 5
- 210000000813 small intestine Anatomy 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 206010058108 Dyslipidaemia Diseases 0.000 claims description 4
- 206010015037 Epilepsy Diseases 0.000 claims description 4
- 210000002216 Heart Anatomy 0.000 claims description 4
- 206010061227 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 210000002027 Muscle, Skeletal Anatomy 0.000 claims description 4
- 210000001550 Testis Anatomy 0.000 claims description 4
- 210000001541 Thymus Gland Anatomy 0.000 claims description 4
- 201000008779 central nervous system disease Diseases 0.000 claims description 4
- 230000019771 cognition Effects 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 230000001771 impaired Effects 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 201000010874 syndrome Diseases 0.000 claims description 4
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 3
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 3
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 3
- 208000008208 Craniocerebral Trauma Diseases 0.000 claims description 3
- 210000001652 Frontal Lobe Anatomy 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010033799 Paralysis Diseases 0.000 claims description 3
- 206010061536 Parkinson's disease Diseases 0.000 claims description 3
- 206010061920 Psychotic disease Diseases 0.000 claims description 3
- 206010040984 Sleep disease Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000001149 cognitive Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims description 3
- 230000000750 progressive Effects 0.000 claims description 3
- 230000000069 prophylaxis Effects 0.000 claims description 3
- 230000000542 thalamic Effects 0.000 claims description 3
- 201000004810 vascular dementia Diseases 0.000 claims description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 2
- VZIHTQKMHLOIII-UHFFFAOYSA-N 3,5-dihydro-2H-furan Chemical group [CH]1CCOC1 VZIHTQKMHLOIII-UHFFFAOYSA-N 0.000 claims description 2
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 206010027175 Memory impairment Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 5
- 108009000047 Alzheimers Disease Proteins 0.000 abstract description 2
- 230000028252 learning or memory Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 239000003480 eluent Substances 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- 238000004128 high performance liquid chromatography Methods 0.000 description 42
- 239000000126 substance Substances 0.000 description 39
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 31
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 28
- 230000000875 corresponding Effects 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 230000002829 reduced Effects 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- JKEKMBGUVUKMQB-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JKEKMBGUVUKMQB-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000007858 starting material Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- ZOOGRGPOEVQQDX-KHLHZJAASA-N Cyclic Guanosine Monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 239000008079 hexane Substances 0.000 description 13
- 230000000051 modifying Effects 0.000 description 13
- 239000003643 water by type Substances 0.000 description 13
- 238000004166 bioassay Methods 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical class N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 10
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- YSHOWEKUVWPFNR-UHFFFAOYSA-N Burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- IUYQIJQHYDZUDF-UHFFFAOYSA-N pyrazolo[3,4-d]pyrimidin-4-one Chemical compound O=C1N=CN=C2N=NC=C12 IUYQIJQHYDZUDF-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 6
- CFHGBZLNZZVTAY-UHFFFAOYSA-N Lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 101700084262 PDE1C Proteins 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000003042 antagnostic Effects 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 125000004432 carbon atoms Chemical group C* 0.000 description 6
- 210000004027 cells Anatomy 0.000 description 6
- 238000003821 enantio-separation Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 230000005526 G1 to G0 transition Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000004031 partial agonist Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 102100014456 PDE1C Human genes 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940093499 ethyl acetate Drugs 0.000 description 4
- 230000002349 favourable Effects 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrugs Drugs 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- OYPPVKRFBIWMSX-SXGWCWSVSA-N (Z)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 3
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 3
- WSEQXVZVJXJVFP-FQEVSTJZSA-N Escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 3
- 102100006616 GRM2 Human genes 0.000 description 3
- 102000001253 Protein Kinases Human genes 0.000 description 3
- 108060006633 Protein Kinases Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- UMGDCJDMYOKAJW-UHFFFAOYSA-N Thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 3
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N Trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108060002036 pde-2 Proteins 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000002469 receptor inverse agonist Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 229960002431 trimipramine Drugs 0.000 description 3
- REZGGXNDEMKIQB-UHFFFAOYSA-N 1,4-Dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 description 2
- OEICGMPRFOJHKO-UHFFFAOYSA-N 2-(ethoxymethylidene)propanedinitrile Chemical compound CCOC=C(C#N)C#N OEICGMPRFOJHKO-UHFFFAOYSA-N 0.000 description 2
- DUGMCDWNXXFHDE-VZYDHVRKSA-N 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C([C@@H](NC(=O)C(C)(N)C)C(=O)N1CCC2(C3=CC=CC=C3N(C2)S(C)(=O)=O)CC1)OCC1=CC=CC=C1 DUGMCDWNXXFHDE-VZYDHVRKSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical class OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- DZFSPRQTWLIERI-UHFFFAOYSA-N 5-amino-1-(4,4-difluorocyclohexyl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=O)N)C=NN1C1CCC(F)(F)CC1 DZFSPRQTWLIERI-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 102100007451 ANAPC1 Human genes 0.000 description 2
- PXAJQJMDEXJWFB-UHFFFAOYSA-N Acetone oxime Chemical compound CC(C)=NO PXAJQJMDEXJWFB-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- 229950004826 Capromorelin Drugs 0.000 description 2
- KVLLHLWBPNCVNR-SKCUWOTOSA-N Capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 description 2
- 208000008787 Cardiovascular Disease Diseases 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L Copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- KYYIDSXMWOZKMP-UHFFFAOYSA-N Desvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N Duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N EXELON Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- 229960001582 Fenfluramine Drugs 0.000 description 2
- 102000027732 GABAA receptors Human genes 0.000 description 2
- 108091008003 GABAA receptors Proteins 0.000 description 2
- 229960003980 Galantamine Drugs 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- 210000001320 Hippocampus Anatomy 0.000 description 2
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N Homotaurine Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 2
- 201000001971 Huntington's disease Diseases 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N Milnacipran Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N Obedrex Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- 102100003490 PDE2A Human genes 0.000 description 2
- 101700078180 PDE2A Proteins 0.000 description 2
- 210000004129 Prosencephalon Anatomy 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N RIFAMPICIN Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229940081190 Rifampin Drugs 0.000 description 2
- 108091006378 SLC25A24 Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229940118176 Surmontil Drugs 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N Tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- 229960001685 Tacrine Drugs 0.000 description 2
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N Thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N Trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
- GKASDNZWUGIAMG-UHFFFAOYSA-N Triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N Trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229940046009 Vitamin E Drugs 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003281 allosteric Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000024881 catalytic activity Effects 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 229960001623 desvenlafaxine Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229960002866 duloxetine Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 2
- 229940076716 ibutamoren mesylate Drugs 0.000 description 2
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 229960004136 rivastigmine Drugs 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- BLFQGGGGFNSJKA-XHXSRVRCSA-N sertraline hydrochloride Chemical compound Cl.C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 BLFQGGGGFNSJKA-XHXSRVRCSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- 239000012414 tert-butyl nitrite Substances 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- 229950005371 zaprinast Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4R,7E,9aS)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (E)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
- LQGZMKDJRWNKAR-BTJKTKAUSA-N (Z)-but-2-enedioic acid;3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine Chemical compound OC(=O)\C=C/C(O)=O.C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 LQGZMKDJRWNKAR-BTJKTKAUSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- XTYLJMKJLMHFJK-UHFFFAOYSA-N 1,1,3,3-tetraethoxy-2-methylpropane Chemical compound CCOC(OCC)C(C)C(OCC)OCC XTYLJMKJLMHFJK-UHFFFAOYSA-N 0.000 description 1
- ZQGWBPQBZHMUFG-UHFFFAOYSA-N 1,1-dimethylthiourea Chemical compound CN(C)C(N)=S ZQGWBPQBZHMUFG-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
- JNODQFNWMXFMEV-UHFFFAOYSA-N 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- SADQVAVFGNTEOD-UHFFFAOYSA-N 3-(2-piperidin-4-ylethyl)-1H-indole Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 108091005523 5-HT4 receptors Proteins 0.000 description 1
- 108091005482 5-HT6 receptors Proteins 0.000 description 1
- YWOPXUCLWYGFRD-UHFFFAOYSA-N 5-amino-1-(4-methylpyridin-3-yl)pyrazole-4-carboxamide Chemical compound CC1=CC=NC=C1N1C(N)=C(C(N)=O)C=N1 YWOPXUCLWYGFRD-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 239000000774 AMPA receptor agonist Substances 0.000 description 1
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N Adenosine monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 Adenosine phosphate Drugs 0.000 description 1
- FZSPJBYOKQPKCD-UHFFFAOYSA-N Alaproclate Chemical compound CC(N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-UHFFFAOYSA-N 0.000 description 1
- 229960003225 Alaproclate Drugs 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 229960000836 Amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N Ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 229940025141 Anafranil Drugs 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000007109 Arundinaria gigantea Species 0.000 description 1
- 210000004227 Basal Ganglia Anatomy 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000003996 CFU-GM Anatomy 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940047493 Celexa Drugs 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 229940109275 Cyclamate Drugs 0.000 description 1
- 229940029644 Cymbalta Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N DL-alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N DME dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- 229960002887 Deanol Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N Dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 Dipyridamole Drugs 0.000 description 1
- 229960005426 Doxepin Drugs 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 229940022766 EGTA Drugs 0.000 description 1
- 229940098766 Effexor Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N Ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229920000665 Exon Polymers 0.000 description 1
- 229960002464 Fluoxetine Drugs 0.000 description 1
- 229960004038 Fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-UHFFFAOYSA-N Fluvoxamine Chemical compound COCCCCC(=NOCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-UHFFFAOYSA-N 0.000 description 1
- 102000012074 GAF domain Human genes 0.000 description 1
- 108050002598 GAF domain Proteins 0.000 description 1
- 102100008842 GH1 Human genes 0.000 description 1
- 102100006614 GRM3 Human genes 0.000 description 1
- 102100006612 GRM5 Human genes 0.000 description 1
- 240000002883 Ginkgo biloba Species 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N Guanosine monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 102100016833 HRH3 Human genes 0.000 description 1
- 101700063464 HRH3 Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229960002102 Imipramine Hydrochloride Drugs 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N Leelamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- 229940054157 Lexapro Drugs 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N Lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 229940009622 Luvox Drugs 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N MeOH methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 1
- 230000035532 Michaelis-Menten constant Effects 0.000 description 1
- 229960000600 Milnacipran Drugs 0.000 description 1
- 102000007205 Muscarinic M2 Receptor Human genes 0.000 description 1
- 108010008407 Muscarinic M2 Receptor Proteins 0.000 description 1
- 102000007216 Muscarinic M4 Receptor Human genes 0.000 description 1
- 108010008414 Muscarinic M4 Receptor Proteins 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N N-benzyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N N-ethyl-N-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-methyl-D-aspartate receptors Human genes 0.000 description 1
- 108090001041 N-methyl-D-aspartate receptors Proteins 0.000 description 1
- MLBHFBKZUPLWBD-UHFFFAOYSA-N Norfenfluramine Chemical compound CC(N)CC1=CC=CC(C(F)(F)F)=C1 MLBHFBKZUPLWBD-UHFFFAOYSA-N 0.000 description 1
- 229940087480 Norpramin Drugs 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 210000000956 Olfactory Bulb Anatomy 0.000 description 1
- 102100017568 PDE11A Human genes 0.000 description 1
- 101710031110 PDE11A Proteins 0.000 description 1
- 102100014454 PDE1A Human genes 0.000 description 1
- 101700006323 PDE1A Proteins 0.000 description 1
- 102100014455 PDE1B Human genes 0.000 description 1
- 101700071589 PDE1B Proteins 0.000 description 1
- 101700034664 PDE5A Proteins 0.000 description 1
- 102100018801 PDE5A Human genes 0.000 description 1
- 102100000432 PDE6A Human genes 0.000 description 1
- 101700006743 PDE6A Proteins 0.000 description 1
- 102100005346 PDE8A Human genes 0.000 description 1
- 101700080696 PDE8A Proteins 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940001408 Paxil Drugs 0.000 description 1
- 108060002038 Pde4 Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229940093430 Polyethylene Glycol 1500 Drugs 0.000 description 1
- 229940093429 Polyethylene Glycol 6000 Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940014148 Pristiq Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 229940035613 Prozac Drugs 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 229960002073 Sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N Sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229960004793 Sucrose Drugs 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N Sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N Sulfanilic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 210000003478 Temporal Lobe Anatomy 0.000 description 1
- VCVWXKKWDOJNIT-ZOMKSWQUSA-N Tesofensine Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2COCC)=CC=C(Cl)C(Cl)=C1 VCVWXKKWDOJNIT-ZOMKSWQUSA-N 0.000 description 1
- 229950009970 Tesofensine Drugs 0.000 description 1
- 229940041597 Tofranil Drugs 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229960003991 Trazodone Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940020965 Zoloft Drugs 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazonic acid Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 102000019633 alpha-2 adrenergic receptor family Human genes 0.000 description 1
- 108020004101 alpha-2 adrenergic receptor family Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 125000005337 azoxy group Chemical group [N+]([O-])(=N*)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- HSUIVCLOAAJSRE-UHFFFAOYSA-N bis(2-methoxyethyl) benzene-1,2-dicarboxylate Chemical compound COCCOC(=O)C1=CC=CC=C1C(=O)OCCOC HSUIVCLOAAJSRE-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical group OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- CLLYAFZCYGRLGE-UHFFFAOYSA-N dithiadiphosphetane Chemical compound P1PSS1 CLLYAFZCYGRLGE-UHFFFAOYSA-N 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 235000004559 haa Nutrition 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229950002473 indalpine Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HWXUMVKTCYWXOI-UHFFFAOYSA-N methyl 2-acetylcyclobutane-1-carboxylate Chemical compound COC(=O)C1CCC1C(C)=O HWXUMVKTCYWXOI-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000000626 neurodegenerative Effects 0.000 description 1
- 230000000324 neuroprotective Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 108010052671 nicotinic receptor alpha4beta2 Proteins 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical compound [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002972 pentoses Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- DTNJZLDXJJGKCM-UHFFFAOYSA-K sodium;trichlorogold Chemical compound [Na].Cl[Au](Cl)Cl DTNJZLDXJJGKCM-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl N-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960002791 zimeldine Drugs 0.000 description 1
Abstract
The invention relates to novel 6-Cycloalkylpyrazolopyrimidinones according to formula (I)
Description
The invention relates to novel 6-Cycloalkylpyrazolopyrimidinones according to formula (I)
Such conditions may for example be associated with Alzheimers disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of médicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibitingproperties.
wherein R1 is a 5 or 6 membered aromatic heteroaryl-group, R2 is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m= 1 or 2 and n is 0, 1 or 2.
The new compounds are for use as the active entity of médicaments or for the manufacture of médicaments respectively, in particular médicaments for the treatment of conditions concerning déficits in perception, concentration, learning or memory.
O.A.P.I. - B.P. 887, YAOUNDE (Cameroun) - Tel. (237) 22 20 57 00- Fax: (237) 22 20 57 27- Site web: http:/www.oapi.int - Email: oapi@oapi.int
Boehringer Ingelheim International GmbH
6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders
The invention relates to novel pyrazolopyrimidinones according to formula (I)
(I),
I 2 wherein R is a 5 or 6 membered aromatic heteroaryl-group, R is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3or 4-pyridyl, m= 1 or 2 and n is 0, 1 or 2.
The new compounds are for use as the active entity of médicaments or for the manufacture of médicaments respectively, in particular médicaments for the treatment of conditions conceming déficits in perception, concentration, leaming or memory. Such conditions may for example be associated with Alzheimer’s disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of médicaments and/or for use in the treatment of these diseases, in particular for cognitive impaîrment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.
BACKGROUND OF THE INVENTION
The inhibition of phosphodiesterase 9A (PDE9A) is one of the current concepts to find new access paths to the treatment of cognitive impairments due to CNS disorders like Alzheimer’s disease, schizophrenia and other diseases or due to any other neurodegenerative process of the brain. With the présent invention, new compounds that follow this concept are presented.
Phosphodiesterase 9A is one member of the wide family of phosphodiesterases. These enzymesmodulate the levels of the cyclic nucléotides 5-3’ cyclic adenosine monophosphate (cAMP) and 5'-3' cyclic guanosine monophosphate (cGMP). These cyclic nucléotides (cAMP and cGMP) are important second messengers and therefore play a central rôle in cellular signal transduction cascades. Each of them réactivâtes inter alia, but not exclusively, protein kinases. The protein kinase activated by cAMP is called protein kinase A (PKA) and the protein kinase activated by cGMP is called protein kinase G (PKG). Activated PKA and PKG are able in tum to phosphorylate a number of cellular effector proteins (e.g. ion channels. Gprotein-coupled receptors, structural proteins, transcription factors). It is possible in this way for the second messengers cAMP and cGMP to control a wide variety of physiological processes in a wide variety of organs. However, the cyclic nucléotides are also able to act dîrectly on effector molécules. Thus, it is known, for example, that cGMP is able to act directly on ion channels and thus is able to influence the cellular ion concentration (review in: Wei et al., Prog. Neuroblol., 1998, 56, 37-64). The phosphodiesterases (PDE) are a control mechanism for the activity of cAMP and cGMP and thus in tum for the corresponding physiological processes. PDEs hydrolyse the cyclic monophosphates to the inactive monophosphates AMP and GMP. Currently, 11 PDE families hâve been defined on the basis of the sequence homology of the corresponding genes. Individual PDE genes within a family are differentiated by letters (e.g. PDE1A and PDE1B). If different splice variants within a gene also occur, then this is indicated by an additional numbering after the letters (e.g. PDE1A1).
Human PDE9A was cloned and sequenced in 1998. The amino acid identity with other PDEs does not exceed 34% (PDE8A) and is never less than 28% (PDE5A). With a MichaelisMenten constant (Km) of 170 nanomolar (nM), PDE9A has high affinity for cGMP. In addition, PDE9A is sélective for cGMP (Km for cAMP=230 micromolar (μΜ)). PDE9A has no cGMP binding domain, suggesting that the enzyme activity is not regulated by cGMP. It was shown in a Western blot analysis that PDE9A is expressed in humans inter alia in testes, brain, small intestine, skeletal muscle, heart, lung, thymus and spleen. The highest expression was found in the brain, small intestine, kidney, prostate, colon and spleen (Fisher et al., J. Biol. Chem., 1998, 273 (25), 15559-15564; Wang et al., Gene, 2003, 314, 15-27). The gene for human PDE9A is located on chromosome 21q22.3 and comprises 21 exons. 4 alternative splice variants of PDE9A hâve been identified (Guipponi et al., Hum. Genet., 1998,103, 386- /
-216302
392). Classical PDE inhibitors do not inhibit human PDE9A. Thus, 1BMX, dipyridamole, SKF94120, rolîpram and vinpocetine show no inhibition on the isolated enzyme in concentrations of up to 100 micromolar (μΜ). An IC50 of 35 micromolar (μΜ) has been demonstrated for zaprinast (Fisher et ai, J. Biol. Chem., 1998, 273 (25), 15559-15564).
Murine PDE9A was cloned and sequenced in 1998 by Soderling et al. (J. Biol. Chem., 1998, 273 (19), 15553-15558). This has, like the human form, high affinity for cGMP with a Km of 70 nanomolar (nM). Particularly high expression was found in the mouse kidney, braîn, lung and liver. Murine PDE9A is not inhibited by IBMX in concentrations below 200 micromolar either; the IC50 for zaprinast is 29 micromolar (Soderling et al., J. Biol. Chem., 1998, 273 (19), 15553-15558). It has been found that PDE9A is strongly expressed in some régions of the rat brain. These include olfactory bulb, hippocampus, cortex, basal ganglia and basal forebrain (Andreeva et al., J. Neurosci., 2001, 21 (22), 9068-9076). The hippocampus, cortex and basal forebrain in particular play an important rôle in leaming and memory processes. As already mentioned above, PDE9A is distinguished by having particularly high affinity for cGMP. PDE9A îs therefore active even at low physiological concentrations, in contrast to PDE2A (Km=10 micromolar (μΜ); Martins et al., J. Biol. Chem., 1982, 257, 1973-1979), PDE5A (Km=4 micromolar (μΜ); Francis et al., J. Biol. Chem., 1980, 255, 620-626), PDE6A (Km=17 micromolar (μΜ); Gillespie and Beavo, J. Biol. Chem., 1988, 263 (17), 8133-8141) and PDE11A (Km=0.52 micromolar (μΜ); Fawcett et al., Proc. Nat. Acad. Soi., 2000, 97 (7), 3702-3707). In contrast to PDE2A (Murashima et al., Biochemistry, 1990, 29, 5285-5292), the catalytic activity of PDE9A is not increased by cGMP because it has no GAF domain (cGMP-binding domain via which the PDE activity is allosterically increased) (Beavo et al., Current Opinion in Cell Biology, 2000, 12, 174-179). PDE9A inhibitors may therefore lead to an increase in the baseline cGMP concentration.
This outlîne will make it évident that PDE9A engages into spécifie physiological processes in a characteristic and unique manner, which distinguishes the rôle of PDE9A characteristically from any of the other PDE family members.
WO 2004/099210 discloses 6-arylmethyl-substituted pyrazolopyrimidinones which are PDE9 inhibitors.
WO 2004/099211 discloses 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines and their use for the improvement of cognition, concentration etc.. /
-316302
DE 102 38 722 discloses the use of PDE9A-inhibitors for the improvement of cognition, concentration.
WO 2004/018474 discloses phenyl-substituted pyrazolopyrimidines and their use for the improvement of perception, concentration leaming and/or memory. /
WO 2004/026876 discloses alkyl-substituted pyrazolopyrimidines which and their use for the improvement of awareness, concentration leaming capacity and/or memory performance. WO 2004/096811 discloses heterocyclic bicycles as PDE9 inhibitors for the treatment of diabètes, including type 1 and type 2 diabètes, hyperglycemia, dyslipidemia, impaired glucose tolérance, metabolic syndrome and/or cardiovascular disease.
W02009068617 discloses PDE9 inhibitîng compounds derived from pyrazolopyrimidinones with a substituted phenylmethyl- or pyridyl-methyl group in the 6-position.
WO2010112437 discloses PDE9 inhibitîng compounds derived from pyrazolopyrimidinones with a phenyl or heteroaryl substituted arylmethyl- or heteroaryl-methyl group in the 6position.
WO 2009/121919 discloses PDE9 inhibitors derived from pyrazolopyrimidinones with a nonaromatic heterocyclyl group in the 1-position, among which is tetrahydropyranyl.
WO 2010/026214 discloses PDE9 inhibitors derived from pyrazolopyrimidinones with a cycloalkyl or a cycloalkenyl group in the 1 -position, among which is 4,4difluorocyclohexyl.
Some prior art is directed to chemically nucleoside dérivatives. As examples it îs referred to WO 2002/057425, which discloses nucleoside dérivatives, which are inhibitors of RNAdependent RNA viral polymerase, or WO 2001/060315, which discloses nucleoside dérivatives for the treatment of hepatitis C infection or EP679657, which discloses compounds that serve as ribonucleoside analogues or US2002058635, which discloses purine L-nucleoside compounds, in which both the purine rings and the carbohydrate ring (pentose ring) are either modified, functionalized, or both. So the carbohydrate ring for example must show at least one esterified hydroxy group.
WO 2005/051944 discloses oxetane-containîng nucleosides, for the treatment of nucleoside analogue related disorders such as disorders involving cellular prolifération and infection. WO 2006/084281 discloses inhibitors ofthe El activation enzyme that hâve a sulfonamide moiety. z
-416302
WO 1998/40384 discloses pyrazolopyrimidinones which are PDE1, 2 and 5 inhibitors and can be employed for the treatment of cardiovascular and cerebrovascular disorders and disorders of the urogénital System.
CH396 924, CH396 925, CH396 926, CH396 927, DE1147234, DE1149013, describe pyrazolopyrimidines which hâve a coronary-dilating effect and which can be employed for the treatment of disturbances of myocardial blood flow.
US3732225 describes pyrazolopyrimidines which hâve an anti-inflammatory and blood glucose-lowering effect.
DE2408906 describes styrylpyrazolopyrimidinones which can be employed as antimicrobial and anti-inflammatory agents for the treatment of, for example, oedema.
OBJECTIVE OF THE INVENTION
Changes in the substitution pattern of pyrazolopyrimidinones resuit in interesting changes conceming biological activîty, respectively changes in the affinity towards different target enzymes.
Therefore it îs an objective of the présent invention to provide compounds as herein described, in particular in the claims, that effectîvely modulate PDE9A for the purpose of the development of a médicament, in particular in view of diseases or conditions, the treatment of which is accessible via PDE9A modulation.
It is another objective of the présent invention to provide compounds that are useful for the manufacture of a médicament for the treatment of CNS disorders.
Yet another objective of the présent invention is to provide compounds which show a favourable safety profile.
Another objective of the présent invention is to provide compounds that hâve a favourable selectîvely profile in favour of PDE9A inhibition over other PDE family members and other pharmacological targets and by this may provide an advantage.
Yet another objective is to provide a médicament that may not only serve for treatment but might also be used for the prévention or modification of the corresponding disease or condition. Z
-5 16302
The présent invention further provides a pharmaceutical composition comprising a compound as herein described, in particular in the claims and a pharmaceutically acceptable carrier.
The présent invention further provides a method for the treatment of any of the conditions as described herein in a mammal in need of such treatment, preferably a human, comprising administering to the mammal a therapeutically effective amount of a compound as herein described, in particular in the claims.
The présent invention further provides a compound as herein described, in particular in the claims, for use in a method of treatment of the human or animal body by therapy.
DETAILED DESCRIPTION OFTHE PRESENT INVENTION
The compounds of the présent invention are characterised by general formula (I):
wherein
R1: is a 5 or 6 membered heteroaryl-group whereby 1, 2, 3 or 4, preferably 1, 2 or 3, of the ring atoms are heteroatoms that are selected independently of each other from N, O or S, whereby said 5 or 6 membered aromatic heteroaryl-group optionally may be substituted by 1, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, HO-, NC-, F3C-, HF2C-, Fl 12C- methyl, H2N- and (CH3)2N-;
R2: is selected from the group consisting of fluorine, NC-, F3C-, HF2C-, FH2C- and methyl, preferably fluorine, NC-, F3C- and methyl;
D: is selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, 2-, 3- and 4-pyridyl, _✓
-616302 whereby cvclopentyl and cvclohexyl optionally may be substituted by l or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, NC-, F3C-, HF2C- and FH2C-;
whereby tetrahydrofuranyl and tetrahydropyranyl optionally may be substituted by l or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, NC-, F3C-, HF2C- andFH2C- ;
whereby pyridyl optionally may be substituted by 1, 2, 3 or 4 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C-, F3C-CH2-, Cj.
6-alkyl- and C37-cycloaIkyl;
m: is selected ftom 1 or 2, preferably 1 ;
n: is selected from 0, 1 or 2, preferably, 0 or 1, more preferably 0, whereby if n = 2, these two groups R2 are selected independently of one another;
and salts, preferably pharmaceutically acceptable salts thereof, solvatés thereof and the solvatés of the aforementioned salts thereof;
with the proviso that the compound is not the following oxadiazolyl-derivative
be it in the form of any possible stereoisomer or a mixture of ail or some thereof or sait thereof or solvaté thereof or a solvaté of a sait thereof.
This embodiment is embodiment 1 of the présent invention.
Conceming the proviso définition above: it shall be understood that throughout this description this définition of the compound, specifically /
-716302 “the following oxadiazolyl-derivative
be it in the form of any possible stereoisomer or a mixture of ail or some thereof’ encompasses the following stereoisomers beside the mixtures of these compounds:
Embodiment 2 of the présent invention: Another embodiment of the invention concems a compound according to general formula (I), wherein
R1: is a 5 or 6 membered heteroaryl-group whereby 1, 2, 3 or 4, preferably 1, 2 or 3, of the ring atoms are heteroatoms that are selected independently of each other from N, O or S, /
-816302 whereby said 5 or 6 membered aromatic heteroaryl-group optionally may be substituted by 1, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C- methyl, H2N- and (CH3)2N-;
R2: is selected from the group consisting of fluorine, NC-, F3C-, HF2C-, FH2C- and methyl, preferably fluorine, NC-, F3C- and methyl;
D: is selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, 2-, 3- and 4-pyridyl, whereby cyclopentyl and cyclohexyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- and FH2C-;
whereby tetrahydrofuranyl and tetrahydropyranyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- andFH2C- ;
whereby pyridyl optionally may be substituted by 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 1 or 2, substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C-, F3C-CH2-, Cl6-alkyl- and C3.7-cycloalkyl;
m: is selected from 1 or 2, preferably m is 1 ;
n: is selected from the group consisting 0, 1 or 2, preferably n is 0 or 1, more preferably n is 0, whereby if n = 2, these two groups R are selected independently of one another;
and salts, preferably pharmaceutically acceptable salts thereof, solvatés thereof and the solvatés of the aforementioned salts thereof;
with the proviso that the compound is not the following oxadiazolyl-derivative r
-916302
be it in the form of any possible stereoisomer or a mixture of ail or some thereof or sait thereof or solvaté thereof or a solvaté of a sait thereof.
Embodiment 3 of the présent invention: Another embodiment of the invention concems a compound according to general formula (I), wherein
R1: is a 5 membered heteroaryl-group whereby 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 2 or 3 of the ring atoms are heteroatoms that are selected independently of each other from N, O or S, whereby said 5 membered aromatic heteroaryl-group optionally may be substituted by
1, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-,FH2C- methyl, H2N- and (CH3)2N-;
R2: is selected from the group consisting of fluorine, NC-, F3C-, HF2C-, FH2C- and methyl, preferably fluorine, NC-, F3C- and methyl;
D: is selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyi, tetrahydropyranyl, 2-, 3- and 4-pyridyl, whereby cyclopentyl and cyclohexyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- and FH2C-;
whereby tetrahydrofuranyi and tetrahydropyranyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- and FH2C- ;
whereby pyridyl optionally may be substituted by 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 1 or 2, substituents, whereby said substituents may be selected s
- 1016302 independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F’,C-, HF2C-, FH2C- F3C-CH2-, Ci^-alkyl- and C3_7-cycloalkyl;
m: is selected from 1 or 2, preferably m is 1 ;
n: is selected from 0, 1 or 2, preferably n is 0 or 1, more preferably n îs 0, whereby if n = 2, these two groups R are selected independently of one another;
and salts, preferably pharmaceutically acceptable salts thereof, solvatés thereof and the solvatés of the aforementioned salts thereof;
with the proviso that the compound is not the following oxadiazolyl-derivative
be it in the form of any possible stereoisomer or a mixture of ail or some thereof or sait thereof or solvaté thereof or a solvaté of a sait thereof.
Embodiment 4 of the présent invention: Another embodiment of the invention concems a compound according to general formula (I), wherein
R1: is a 6 membered heteroaryl-group whereby 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 2 or 3 of the ring atoms are heteroatoms that are selected independently of each other from N, O or S, whereby said 6 membered aromatic heteroaryl-group optionally may be substituted by 1, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C-, methyl, H2N- and (CH3)2N-;
R2: is selected from the group consisting of fluorine, NC-, F3C-, HF2C-, FH2C- and methyl, preferably fluorine, NC-, F3C- and methyl; Z
- 11 16302
D: is selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, 2-, 3- and 4-pyridyl, whereby cyclopentyl and cyclohexyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- and FH2C-;
whereby tetrahydrofuranyl and tetrahvdropyranvl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- and FH2C- ;
whereby pyridyl optionally may be substituted by 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 1 or 2, substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C-, F3C-CH2-, C].6-alkyi- and C3.7-cycloalkyl;
m: is selected from 1 or 2, preferably m is 1 ;
n: is selected from 0, 1 or 2, preferably n is 0 or 1, more preferably n is 0, whereby if n = 2, these two groups R are selected independently of one another;
and salts, preferably pharmaceutically acceptable salts thereof, solvatés thereof and the solvatés of the aforementioned salts thereof.
Embodiment 5 of the présent invention: Another embodiment of the invention concems a compound according to general formula (I), wherein
R1: is a heteroaryl-group selected from the group consisting of thiadiazolyl, oxadiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyridyl and pyrimidînyl, preferably said heteroaryl-group being selected from the group consisting of thiadiazolyl, oxadiazolyl, isoxazolyl, thiazolyl, oxazolyl and pyrimidînyl, whereby said heteroaryl-group optionally may be substituted by 1, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C- methyl, H2N- and (CH3)2N-;
R2: is selected from the group consisting of fluorine, NC-, F3C-, HF2C-, FH2C- and methyl, preferably fluorine, NC-, F3C- and methyl;
D: îs selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, 2-, 3- and 4-pyridyl,
- 1216302 whereby cyclopentyl and cyclohexyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consîsting of fluorine, F3C-, HHC- and FH2C-;
whereby tetrahydrofuranyl and tetrahydropyranvl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consîsting of fluorine, F3C-, HF2C- and FH2C- ;
whereby pyridyl optionally may be substituted by 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 1 or 2, substituents, whereby said substituents may be selected independently of one another from the group consîsting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C-, F3C-CH2-, C, 6-alkyl- and C3.7-cycloalkyl;
m: is selected from 1 or 2, preferably m is 1 ;
n: is selected from 0, 1 or 2, preferably n is 0 or 1, more preferably n is 0, whereby if n = 2, these two groups R2 are selected independently of one another;
and salts, preferably pharmaceutically acceptable salts thereof, solvatés thereof and the solvatés of the aforementîoned salts thereof;
with the proviso that the compound is not the following oxadîazolyl-derivative
be it in the form of any possible stereoisomer or a mixture of all or some thereof or sait thereof or solvaté thereof or a solvaté of a sait thereof.
Embodiment 6 of the présent invention: Another embodiment of the invention concems a compound according to general formula (I), wherein
R1: is a heteroaryl-group selected from the group consîsting of thiadiazolyl, 1,2,3oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyridyl and
- 13 16302 pyrimidinyl, preferably said heteroaryl-group being selected from the group consisting of thiadiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyridyl and pyrimidinyl, whereby said heteroaryl-group optionally may be substituted by 1, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C-, methyl, H2N- and (CH3)2N-;
R2: is selected from the group consisting of fluorine, NC-, F3C-, HF2C-, FH2C- and methyl, preferably fluorine, NC-, F3C- and methyl;
D: is selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, 2-, 3- and 4-pyridyl, whereby cyclopentyl and cyclohexyl optionally may be substituted by 1 or 2 substituents selected from the group consisting of fluorine, F3C-, HF2C- and FH2C-;
whereby tetrahydrofuranyl and tetrahydropyranyl optionally may be substituted independently of one another by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- andFH2C-;
whereby pyridyl optionally may be substituted by 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 1 or 2, substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C-, F3C-CH2-, C^-alkyl- and C3.7-cycloalkyl;
m: is selected from 1 or 2, preferably m is 1 ;
n: is selected from 0, 1 or 2, preferably n is 0 or 1, more preferably n is 0, whereby if n = 2, these two groups R are selected independently of one another;
and salts, preferably pharmaceutically acceptable salts thereof, solvatés thereof and the solvatés of the aforementioned salts thereof
Embodiment 7 of the présent invention: embodiment 7 of the invention concems a compound that corresponds in ail aspects with embodiment 6, except in that
R1: îs a heteroaryl-group selected from the group consisting of thiadiazolyl, 1,2,3oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, isoxazolyl, thiazolyl, oxazolyl and pyrimidinyl, preferably said heteroaryl-group being selected from the group consisting of thiadiazolyl, isoxazolyl, thiazolyl, oxazolyl and pyrimidinyl,
- 1416302 whereby said heteroaryl-group optionally may be substituted by l, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C- methyl, H2N- and (CH3)2N-.
Embodiment 8 of the présent invention: Another embodiment of the invention concerns a compound according to general formula (1), wherein
R1: is a heteroaryl-group selected from the group consisting of [l,3,4]thiadiazol-2-yl, isoxazol-5-yl, thiazol-5-yl-, oxazol-2-yl, pyridin-2-yl and pyrimidin-2-yl, preferably said heteroaryl-group being selected from the group consisting of [l,3,4]thiadiazol-2-yl, isoxazol5-yl, thîazol-5-yl-, oxazol-2-yl and pyrimidin-2-yl, whereby said heteroaryl-group optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, CN-, methyl and H2N-;
R2: is selected from the group consisting of fluorine, NC-, F3C-, HF2C-, FH2C- and methyl, preferably fluorine, NC-, F3C- and methyl;
D: is selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, 2-, 3- and4-pyridyl whereby cyclopentyl and cyclohexyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- andFH2C-; preferably by fluorine;
whereby tetrahydrofuranyl and tetrahydropyranyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- and FH2C- ;
whereby pyridyl optionally may be substituted by 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 1 or 2, substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C-, F3C-CH2- and methyl;
whereby preferably D is selected fforn the group consisting of 4,4-difluorocyclohex-lyl, tetrahydropyranyl, thereof preferably tetrahydropyran-4-yl, and 4-methy-3-pyridyl; m: is selected from 1 or 2, preferably m is 1 ;
n: is selected from 0, 1 or 2, preferably n is 0 or 1, more preferably n îs 0, whereby if n = 2. these two groups R2 are selected independently of one another; s
- 1516302 and salts, preferably pharmaceutically acceptable salts thereof, solvatés thereof and the solvatés of the aforementioned salts thereof.
Embodiments 9 to 16 of the présent invention:
In any of the above mentioned embodiments 1 to 8 the preferred compounds are represented by formula (II):
Compounds according to formula (II)
with
R1: as defined in any of the aforementioned embodiments 1 to 8;
D being either 4,4-difluorocyclohexyl or tetrahydropyran-4-yl or 4-methy-3-pyridyl and none of these two groups has further substituents;
and salts, preferably pharmaceutically acceptable salts thereof, solvatés thereof and the solvatés of the aforementioned salts thereof;
with the proviso that the compound is not the following oxadiazolyl-derivative
be it in the form of any possible stereoisomer or a mixture of ail or some thereof or sait thereof or solvaté thereof or a solvaté of a sait thereof. s
- 1616302
The preferred embodiments 9 to 16 according to formula (II) dérivé from embodiments according to formula (I) in that:
m in formula (I) is 1, so that the corresponding cycloalkyl-group is a cyclobutyl;
n in formula (I) is 0;
D in formula (I) is selected from the group of 4,4-difluorocyclohexyl (wîthout further substituents, i.e. unsubstituted) and tetrahydropyran-4-yl (wîthout further substituents, i.e. unsubstituted) and 4-methy-3-pyridyl;
R1 in formula (I) îs attached to said aforementioned cyclobutyl (m=l) in the 2-position thereof while the 1 position of said cyclobutyl is the attachment point to the 6 position of the D-substituted pyrazolopyrimidinone.
The corresponding embodiments are designated as embodiments 9, 10, 11,12, 13, 14, 15 and 16 respectively.
Embodiment 9 dérivés from embodiment 1, embodiment 10 from embodiment 2, embodiment 11 from embodiment 3, embodiment 12 from embodiment 4, embodiment 13 from embodiment 6, embodiment 14 from embodiment 6, embodiment 15 from embodiment Ί, embodiment 16 from embodiment 7.
Embodiments 17 to 24 of the présent invention:
Within each of the above mentioned embodiments 1 to 16 more preferred compounds are represented by formula (II):
N
with
R1: as defined in any of the aforementioned embodiments 1 to 8;
- 1716302
D being either 4,4-difluorocyclohexyl or tetrahydropyran-4-yl and none of these two groups has further substituents;
and salts, preferably pharmaceutically acceptable salts thereof, solvatés thereof and the 5 solvatés of the aforementioned salts thereof, with the proviso that the compound is not the following oxadiazolyl-derivatîve
a mixture of ail or some thereof or sait thereof or solvaté thereof or a solvaté of a sait thereof.
For ail embodiments 1 to 24: the configuration of the cycloalkyl group at position 6 of the pyrazolopyrimidinones group with respect to said pyrazolopyrimidinones group and the substituent R1 may be cis or trans.
In this respect the compounds of the invention may hâve the following configurations:
trans configuration 1 | trans configuration 2 | ||||
0 | 0 | ||||
Y- | |||||
R< | H 1 | N | R'J | H l | N |
..... | \ > Ζγ N | ||||
(R2)n | Y | 1 D | (R2)—ί | ¥ | I D |
cis configuration 1 | cis configuration 2 |
- 1816302
whereby Rl, R2, m, n and D are as defined in any of embodiments 1 to 8.
These stereochemically defined embodiments are a further aspect of the invention.
Embodiment 25 of the présent invention:
Within the context of the présent invention one or more compound(s) is (are) preferred that are selected from the group of specifically defined species as listed in the following table. The left column contains a letter code to identify the compound family, which is the group of compounds that hâve the same general chemical structural formula if no stereochemical 10 properties are considered. Members of these compound families are exemplified in the section Exemplary embodiments.
Table of species:
- 1916302
-2016302
Compound family C, covering example 3 , | |
c a | 0 M in f! N, ô |
C b | b° fSp. ΆΑ Y , |
C c | 0 A/° A Hï iPn zb ^-o |
C d | ο ηΛα b A |
D | γ 0 N=V | 0 HN^ if A. A N | X / N | |
% F | 2 | |||
Compound | family | D, covering | ||
example 4 | > | |||
D a | N 0 N=Z | O hAA A J ' N | X _ / N b | \ |
b F | SF | |||
D b | V θ A b | Λ A | X -E b | \ |
b F | F , | |||
D c | y 0 | 0 HN^ |r | X / ~N b | \ |
X F |
-2116302
-22 16302
Compound family Gl, covering example 7
-2316302
G 2 | 0 Λ HN Υί | fV Niy |
Compound example 8 | family G2, covering | |
G | 0 II | |
2 | ηκΛ | x |
Γ7 N | \ / | |
H Nr | A | |
G | 0 II | |
2 b | ηνΛ λΑν' | o |
>-<? X | A N--/ | |
G | 0 II | |
2 c | V | » |
y? | H | |
U | n=z7 | |
r | 9 |
-2416302
-2516302
-2616302
-2716302
Μ a | //Ν Μ Ηϊ \yANAN' ζ |
Μ b | A -A Α·Λ^ |
Μ c | Μ 0 A> JA A// ην ΊτΑ b y n v Z |
Μ d | A A» Α-χί |
-2816302
N | I Q | ||||
V Compound example 20 | 'y'x+J | A / ~N S covering > | |||
famîly | N, | ||||
N | l | 0 | |||
a | |||||
M | HlA I | T | A / 'N | ||
Λ | < | ||||
/ ’ | |||||
N | / | 0 | |||
b | 1 | ||||
\ // S—Y | HNX | V | A | ||
't | -ν' | ||||
Λ | < | ||||
/ ’ | |||||
N | I | 0 | |||
c | v> | ||||
M | H A | Λ | |||
Y-ff N | / N \ | ||||
c | < | ||||
/ ’ |
N d | / o | ||
A i | Λ HN A 7' N' | A À · | |
O | A N=/ | 0 | |
HN^ ιΓ | A | ||
Aa C- ' N | / N (b | ||
A | |||
Compound example 21 | famîly | 0, covering | |
0 | 0 | ||
..-A V o | |||
a | \ ! | hiA At AI ' N | A / ''N (b |
h | |||
0 | 0 | ||
b | N 0 N=/ | A | A |
b | A? | A | |
A ’ |
-2916302
- 30Boehringer Ingelheim
P01 -2xxx-Prio
--31-16302
-3216302
S | 0 [I | |
d | hnA _ A J a n | X |
A C x> | Qf | |
\=/ | ||
T | „Â L | rfx N |
qAN | A a/ | |
N 7 \=/ | 0 | |
Compound family T, covering | ||
examples 26, 27 | and 28 | |
T a | 0 „A k | rX N 1 / |
C/ | N X/ | |
X-n -o | 0 |
and salts, preferably pharmaceutically acceptable salts thereof, solvatés thereof and the solvatés of the aforementioned salts thereof.
Within the latter group of compounds, compounds that show trans configuration with respect to the substitution at the cyclobutyl-group may be preferred over compounds with ois configuration. Of the possible trans configured compounds one thereof may show advantages in efficacy. The more efficacious a compound the more it is among the preferred compounds.
-3316302
Another criterion which may differentiate preferred compounds according to the invention is the balance of efficacy and safety, such as for example selectivity vs. other PDE family members such as PDEIC.
For one pair of trans configured compounds according to the experimental part a single crystal X-ray structure analysis revealed that the absolute stereochemistry of the compound which showed lower efficacy than its enantiomer is R,R. As a conséquence thereof absolute stereochemistry of the compound with the higher efficacy is S,S.
For said compound the S,S-configuration is represented by the following structure according to general formula (II):
In analogy, one may assume that among the compounds according to embodiment 25, such compounds that show the same absolute stereochemistry might be the more active ones compared with the other members of the same compound family. According to the présent invention, within the same compound family the more active compounds are preferred over the less active compounds. The compound family is the group of compounds that differ in their chemical structure only with regard to stereochemical properties.
The different stereoisomers are subject to individual embodiments according to the invention:
embodiment 26 of the présent invention concems a compound according to any one of embodiments l to 25, whereby the compound shows the following stereochemical properties if the compound generally can be represented by formula (I)::
if the compound generally can be represented by formula (II):
(la),
(Ha).
-3416302 embodiment 27 of the présent invention concems a compound according to any one of embodiments 1 to 25, whereby the compound shows the following stereochemical properties:
if the compound generally can be represented if the compound generally can be represented by formula (I):
(Ib), by formula (II):
(Ilb).
embodiment 28 of the présent invention concems a compound according to any one of embodiments 1 to 25, whereby the compound shows the following stereochemical properties:
if the compound generally can be represented if the compound generally can be represented by formula (I):
(le), by formula (II):
(Hc).
embodiment 29 of the présent invention concems a compound according to any one of embodiments 1 to 25, whereby the compound shows the following stereochemical properties: if the compound generally can be represented if the compound generally can be represented by formula (1): by formula (II):
-3516302
(Id),
(Ild).
Embodiment 30 of the présent invention: Another set of preferred embodiment of the présent invention dérivés from each of the aforementioned embodiments conceming compounds according to formula (I) or (II), inclusively the preferences conceming stereochemical properties thereof, in that
R1 being pyrimidinyl, or pyridyl, preferably pyrimidin-2-yl or pyrdîn-2-yl, m = 1, n = 0 and
D is selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, 2-, 3- and 4-pyridyl whereby cyclopentyl and cyclohexyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, FjC-, HF2C- and FH2C-; preferably by fluorine; whereby tetrahydrofuranyl, tetrahydronyranyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F/C-, HF2C- and FH2C- ;
whereby pyridyl optionally may be substituted by 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 1 or 2, substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C- F3C-CH2- and methyl;
whereby preferably D is selected from the group consisting of 4,4-difluorocyclohex-lyl, tetrahydropyranyl and 4-methy-3-pyridyl and salts, preferably pharmaceutically acceptable salts thereof, solvatés thereof and the solvatés of the aforementioned salts thereof
-3616302
For each of the embodiments l to 30: whenever D may be tetrahydrofuranyl, it is preferably tetrahydrofuran-3-yl; whenever D may be tetrahydropyranyl it is préférable tetrahydropyran-
3-yl or tetrahydropyran-4-yl, more preferably tetrahydropyran-4-yl.
For each of the embodiments 1 to 30: the heteroaryl-group R1 preferably is bound via a carbon ring atom thereof to the cycloalkyl-group that is attached to the 6-position of the pyrazolopyrimidinone-scaffold. According to general formula (I) said cycloalkyl-group may be a cyclobutyl- or cyclopentyl-group, according to general formula (II) said cycloalkylgroup is a cyclobutyl-group.
TERMS AND DEFINITIONS
Ternis not specifically defined herein should be given the meanings that would be given to them by a person skilled in the art in light of the disclosure and the context. Examples include that spécifie substituents or atoms are presented with their 1 or 2 letter code, like H for hydrogen, N for nitrogen, C for carbon, O for oxygen, S for sulphur and the like. Optionally but not mandatory the letter is followed by a hyphen to indicate a bond. As used in the spécification, unless specified to the contrary, the following ternis hâve the meaning indicated and the following conventions are adhered to.
In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, C|.6 alkyl means an alkyl group or alkyl radical having 1 to 6 carbon atoms. In general, for groups comprising two or more subgroups, the last named group is the radical attachment point, for exampïe, (CH3)2N- means a monovalent radical of the formula (CH3)2N-, which is attached via the nitrogen atom thereof (i.e. a dimethylamino-substituent). If the terni of a substituent starts or ends with a minus sign or hyphen, i.e. -, this sign emphasises the attachment point as in the aforementioned example (CH3)2N-, where the N is linked to the group of which the dimethylamino-group is a substituent. Unless otherwise specified below, conventional définitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups.
-3716302
In general, if terms are specifically defined with a given context, such spécifie définitions shall prevail over the more general définitions as outlined in this paragraph.
In general, ail “tautomeric forms and isomeric forms and mixtures”, whether individual géométrie isomers or optical isomers or racemic or non-racemic mixtures of isomers, of a chemical structure or compound are intended, unless the spécifie stereochemistry or isomeric form is specifically indicated in the compound name or structure. Spécifie définitions prevail.
“Substitution”: The term substituted*' as used herein explicitly or implicitly, means that any one or more hydrogen(s) on the designated atom is replaced with a member of the indicated group of substituents, provided that the designated atom's normal valence is not exceeded. In case a substituent is bound via a double bond, e.g. an oxo substituent, such substituent replaces two hydrogen atoms on the designated atom. The substitution shall resuit in a stable compound. “Stable” in this context preferably means a compound that from a pharmaceutical point of view is chemically and physically sufficiently stable in order to be used as an active pharmaceutical ingrédient of a pharmaceutical composition. If a substituent îs not defined, it shall be hydrogen. By the term optionally substituted is meant that either the corresponding group is substituted or it is not. A characterisation that substituents of the same group may be “selected independently of one another” shall mean, that the corresponding substituents may be the same or may be different.
The phrase pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions and/or dosage forms which are, within the scope of Sound medical judgment, suitable for use in contact with the tissues of human beings or as the case may be of animais without excessive toxicity, irritation, allergie response, or other problem or complication, commensurate with a reasonablebenefit/risk ratio.
pharmaceutically acceptable salt(s) of the compounds according to the invention are subject of the présent invention as well. The term pharmaceutically acceptable salt(s) refers to dérivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof, preferably addition salts. Examples of pharmaceutically acceptable salts include, but are not limited to, minerai or organic acid salts of basic residues/parts of the compounds of the présent invention such as aminofonctions; acidic
-3816302 residues/parts within compounds of the présent invention may form salts with alkali or organic bases. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quatemary ammonium salts of the parent compound formed, for example, from nontoxic inorganîc or organic acids. For example, such conventional non-toxic salts include those derived from inorganîc acids such as hydrochloric acid, hydrobromic acid, suliuric acid, sulfamic acid, phosphoric acid, ni trie acid and the like; and the salts prepared from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartane acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acîd, sulfanilic acid, 2acetoxybenzoic acid, fiimaric acid, toluenesulfonic acid, methanesulfonic acid, ethane disulfonic acid, oxalic acid, isethîonic acid and the like.
Physiologically acceptable salts with bases also may include salts with conventional bases such as, by way of example and preferably, alkali métal salts (e.g. sodium and potassium salts), alkaline earth métal salts (e.g. calcium and magnésium salts) and ammonia, organic amines having 1 to 16 C atoms, such as, by way of example and preferably, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, Nm ethyl -morpho line, dehydroabietylamine, arginine, lysine, ethylenediamine and methylpiperidine and the like.
The pharmaceutically acceptable salts of the présent invention can be synthesized from the parent compound with basic or acidic properties by conventional chemical methods. Generally, such salts can be prepared by reacting the free acîd or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, éthanol, isopropanol, or acetonitrile are preferred.
A “Prodrug” is considered a compound that is designed to release a biologically active compound according to the présent invention in-vivo when such prodrug is administered to a mammalian subject. Prodrugs of compounds according to the présent invention are prepared by modifying functional groups présent în the compound of the invention in such a way that these modifications are retransformed to the original functional groups under physiological x
-3916302 conditions. It will be appreciated that prodrugs of the compounds according to the présent inventions are subject to the présent invention as well.
“Métabolites” are considered dérivatives of the compounds according to the présent invention that are formed in-vivo. Active métabolites are such métabolites that cause a pharmacological effect. It will be appreciated that métabolites of the compounds according to the présent inventions are subject to the présent invention as well, in particular active métabolites.
Some of the compounds may form “solvatés”. For the purposes of the invention the term “solvatés” refers to those forms of the compounds which form, in the solid or liquid state, a complex by coordination with solvent molécules. Hydrates are a spécifie form of solvatés in which the coordination takes place with water. According to the présent invention, the term preferably is used for solid solvatés, such as amorphous or more preferably crystalline solvatés.
“Scaffold”: The scaffold of the compounds according to the présent invention is represented by the following core structure. The numération of the positions of the ring member atoms is indicated in bold:
It will be évident for the skilled person in the art, that this scaffold can be described by its tautomeric “enol” form s
-4016302
In the context of the présent invention both structural représentations of the scaffold shall be considered the subject of the présent invention, even if only one of the two représentatives îs presented. Without meant to be limiting or bound, it îs believed that for the majority of compounds under ambient conditions and therewith under conditions which are the relevant conditions for a pharmaceutical composition comprising said compounds, the equilibrium of the tautomeric forms lies on the side of the pyrazolopyrimdin-4-one représentation. Therefore, all embodiments are presented as pyrazolopyrimdin-4-one-derivatives or more precisely as pyrazolo[3,4-d]pyrimidin-4-one dérivatives.
“Bonds”: If within a chemical formula of a ring system or a defined group, a substituent is directly linked to an atom or a group like “RyR” in the formula below, this shall mean that the substituent îs only attached to the corresponding atom. If however from another substituent like “RxR” a bond is not specifically linked to an atom of the ring system but drawn towards the center of the ring or group this means that this substituent “RxR” may be linked to any meaningful atom of the ring system / group unless stated otherwise.
The bond symbol (= minus sign) or the symbol *” (= minus sign followed by an asterisk sign) stands for the bond through which a substituent is bound to the corresponding remaining part of the molécule / scaffold. In cases in that the minus sign does not seem to be sufficiently clear, there may be added an asterisk to the bond symbol in order to détermine the point of attachment of said bond with the corresponding main part of the molécule / scaffold. s
-4l 16302
The term “CX,-alkyl” dénotés a saturated, branched or unbranched hydrocarbon group with 1 to 6 C atoms. Examples of such groups include methyl, ethyl, «-propyl, zso-propyl, butyl, isobutyl, sec-butyl, tert-butyl, «-pentyl, iso-pentyl, «eo-pentyl, ter/-pentyl, «-hexyl, iso-hexyl. This définition applies for the use of “alkyl” in any reasonable context within the présent description in the absence of a further définition.
The term “Ci-v-cycloalkyl” dénotés a saturated monocyclic group with 3 to 7 C ring atoms. Preferred are 5 or 6 membered cycloalkyl-groups. There are no other ring atoms than carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl. This définition applies for “cycloalkyl” in any reasonable context within the présent description in the absence of a further définition.
The term “heteroaryl” used in this application dénotés a heterocyclic, monocyclic aromatic ring System which includes within the ring system itself in addition to at least one C atom one or more heteroatom(s) which are independently selected from N, O and/or S. Preferred are heteroaryls with 1 to 3 heteroatoms or 1 to 2 heteroatoms, or 1 heteroatom. Preferred heteroatom is N.
The terms “pyridyl” defines a pyridine-substituent, sometimes also called pyridinyl.
Expressions like prévention, prophylaxis, prophylactic treatment or préventive treatment used herein should be understood synonymous and in the sense that the risk to develop a condition mentioned hereinbefore is reduced, especially in a patient having elevated risk for said conditions or a corresponding anamnesis. Thus the expression prévention of a disease as used herein means the management and care of an individual at risk of developing the disease prior to the clinical onset of the disease. The purpose of prévention is to combat the development of the disease, condition or disorder and includes the administration of the active compounds to prevent or delay the onset of the symptoms or complications and to prevent or delay the development of related diseases, conditions or disorders. Success of said préventive treatment is reflected statistically by reduced incidence of said condition within a patient population at risk for this condition in comparison to an équivalent patient population without préventive treatment. r
-42 16302
The expression treatment or therapy preferably means therapeutic treatment of (e.g. preferably human) patients having already developed one or more of said conditions in manifest, acute or chronic form, including symptomatic treatment in order to relieve 5 symptoms of the spécifie indication or causal treatment in order to reverse or partially reverse the condition or to delay the progression of the indication as far as this may be possible, depending on the condition and the severity thereof. Thus the expression treatment of a disease as used herein means the management and care of a patient having developed the disease, condition or disorder. The purpose of treatment is to combat the disease, condition, 10 disorder or a symptom thereof. Treatment includes the administration of the active compounds to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complications associated with the disease, condition or disorder.
The following schemes shall illustrate generally how to manufacture the compounds of the présent invention by way of example. The abbreviated substituents may be as defined for the embodiments offormula (I) ifnot defined otherwise within the context ofthe schemes: x .1 8 JAN 2013 ’
ROUN
53
-4316302
Scheme 1
NH3, H2O2
EtOH/H2O
see Scheme 2 (path 2)
u NaH/EtOH
Scheme 1 : In a first step 2-ethoxymethylene-malononitrile is condensed with mono5 substituted hydrazines by heating in an appropriate solvent like éthanol in the presence of a base (e.g. triethylamine) to form the corresponding 5-amino-lH-pyrazole-4-carbonitriles. These compounds are converted in a second step to the corresponding amides, e.g. by treatment of an ethanolic solution with ammonia (25 % in water) and hydrogen peroxide (35 % in water). In a third step, heating with dicarboxylic acid diesters under basic conditions (e.g. sodium hydride in éthanol) followed by the addition of aqueous sodium hydroxide leads /
-4416302 to 4-oxo-4,5-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6-yl substituted carboxylic acids (path 1). The carboxylic acid functional group thereof is converted to a heteroaryl group as described în Scheme 2 yieldîng pyrazolo[3,4-d]pyrimidin-4-ones as final products. Altematively, 4oxo-4,5-dihydro-l 1l-pyrazolo[3,4-d]pyrimidîn-6-yl substituted nîtriles can be synthesized from dinitriles by heating under basic conditions (e.g. sodium hydride in éthanol) in the third step (path 2). The nitrile functional group is further converted to heteroaryl substituents as described in Scheme 3 yieldîng pyrazolo[3,4-d]pyrimidin-4-ones as final products. [cf., for example, A. Miyashîta et al., Heterocycles 1990, 31, 1309ff|.
Scheme 2
Scheme 2: 4-Oxo-4,5-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6-yl substituted carboxylic acids are treated under conditions listed in the table below to form heteroaryl substituted 15 pyrazolo[3,4-d]pyrimidin-4-ones as final products. Ra is a substituent of R1.
conditions as mentioned in scheme 2 | R1 | Ra |
1. ) Reaction with HATU and DIPEA followed by a carboxylic acid hydrazide. 2. ) Treatment with Lawesson’s reagent in THF at elevated températures. | Da__Z N | H-, F3C-, HF2C-, FH2C-, methyl |
1.) Reaction with oxalylchloride in THF followed by treatment with trimethylsilydiazomethane followed by | O * | H-, F3C-, HF2C-, FH2C-, methyl |
-4516302
hydrochloric acid in dioxane. 2.) Reaction with a thioamide in EtOH. | ||
1. ) Reaction with oxalylchloride in THF followed by treatment with trimethylsilydiazomethane followed by hydrochloric acid în dioxane. 2. ) Reaction with a thiourea in EtOH. | H) s V | H-, FjC-, HF2C-, FH2C-t methyl |
3. ) Reaction with oxalylchloride in THF followed by treatment with trimethylsilydiazomethane and hydrochloric acid in dioxane. 4. ) Reaction with a thiourea in EtOH. | S V | H2N-, (CH3)2N- |
1. ) Reaction with TBTU and D1PEA followed by a 2-amino-alkohol. 2. ) Oxîdation with Dess-Martin- Periodinane in dichloromethane. 3. ) Treatment with Burgess-reagent in DME at elevated températures. | V oK | H-, NC-, F3C-, hf2c-, fh2c-, methyl |
1. ) Reaction with TBTU and DIPEA followed by a 2-amino-ketone hydrochloride. 2. ) Treatment with Burgess-reagent in DME at elevated températures. | oV | H-, NC-, F3C-, hf2c-, fh2c-, methyl |
1. ) Reaction with TBTU and DIPEA followed by a 2-amino-alkohol. 2. ) Oxîdation with Dess-Martin- | H-, NC-, F3C-, hf2c-, fh2c-, methyl |
-4616302
Periodinane in dichloromethane. 3.) Treatment with Lawesson’s reagent in THF at elevated températures. | ||
1. ) Reaction with TBTU and DIPEA followed by a 2-amino-ketone hydrochloride. 2. ) Treatment with Lawesson’s reagent in THF at elevated températures. | A S-'A | H-, NC-, F3C-, hf2c-,fh2c-, methyl |
1. ) Reaction with TBTU and DIPEA followed by 1,2-dimethylhydroxylamine hydrochloride. 2. ) Reaction with a mixture prepared separately from propan-2-one oxime and n-buthyllithium followed by treatment with sulfuric acid in THF / water. | k | |
1. ) Reaction with TBTU and DIPEA followed by hydrazîne hydrate. 2. ) Treatment with triethoxymethane at elevated températures. | An <. Jl o-\ |
-4716302
Scheme 3
with
Rx - Me, Et
Ry = NC-, F3C-,
HF2C-, fh2c-, methyl, HScheme 3: 4-Oxo-4,5-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6-yl substituted nîtriles are mixed with methanol and treated with acetylchloride or, altematively, mixed with a saturated 5 solution of hydrochloric acid in éthanol. The intermediates are treated in a second step with a solution of ammonia in methanol to form the corresponding amidînes. Reaction with a
1,1,3,3-tetraalkoxypropane yields pyrimidin-2-yl substituted pyrazolo[3,4-d]pyrimîdin-4-ones as final products.
Further alternative processes for preparing pyrazolo[3,4-d]pyrimidin-4-ones are known in the art and can likewise be employed for synthesizing the compounds of the invention (see, for example: P. Schmidt et al., Helvetica Chimica Acta 1962,189, 1620ff.). /
-4816302
Scheme 4
H NNH
O
reducing agent
is cyclopentyl or cyclohexyl optionally substited as defined in formula (I). Consequently, n = 1 or 2
Scheme 4: The mono-substituted hydrazine dérivatives, that are used in step 1 of scheme 1 can be prepared by reductive amination of a ketone with hydrazinecarboxylic acid tert-butyl ester followed by a deprotection step as shown in scheme 4 for an D being cyclopentyl or cyclohexyl as defined in general formula (I) [c£, for example, J.W. Timberlake et al., “Chemistry of Hydrazo-, Azo- and Azoxy Groups; Patai, S., Ed.; 1975, Chapter 4; S. C. Hung et al., 10 Journal of Organic Chemistry 1981, 46, 5413-5414].
-4916302
Scheme 5
oc2h5 | NH / 2 | ELN/EtOH |
+ | HN 1 | ----► |
1 CN | D | heat |
NH3, HaOg
EtOH/H2O
Scheme 5: As described in scheme 1, in a first step 2-ethoxymethylene-malononitrile is condensed with mono-substituted hydrazines by heating in an appropriate solvent like éthanol in the presence of a base (e.g. triethylamine) to form the corresponding 5-amino-lHpyrazole-4-carbonitriles. These compounds are converted in a second step to the corresponding amides, e.g. by treatment of an ethanolic solution with ammonîa (25 % in water) and hydrogen peroxide (35 % in water). In a third step, heating with R1 and R2 10 substituted cyclobutyl or cyclopentyl carboxylic acid ester under basic conditions (e.g.
sodium hydride în éthanol) leads to the final pyrazolo[3,4-d]pyrimidin-4-ones as final products. [cf„ for example, A. Miyashita et al., Heterocycles 1990, 31, 1309ff]. This procedure is described in more detail for R1 being pyridniyl, m being 1 and n being 0 in the experimental section (examples 29 to 32).
Further information also can be found în:
WO 2004/099210 (in particular page 9, last paragraph to page 14, line 8, incorporated by reference),
- 5016302
- with respect to the general manufacture of compounds with D being tetrahydropyranyl more information can be found in W02009/121919, particularly on page 120 to 125 and the experimental part thereof (herewith incorporated by reference),
- with respect to D being 4,4-difluorocyclohexyl more information can be found in WO 2010/026214, particularly on page 59 to 63 and the experimental part thereof (herewith incorporated by reference), and in the experimental part (exemplary embodiments) of this description. The letter in particular with respect to the manufacture of the two building blocks:
METHOD OF TREAMENT
The présent invention refers to compounds, which are considered effective in the treatment of diseases. The compounds according to the invention are effective and sélective inhibitors of phosphodiesterase 9A and can be used for the development of médicaments. Such médicaments shall preferably be used for the treatment of diseases in which the inhibition of PDE9A can provide a therapeutic, prophylactic or disease modifying effect. Preferably the médicaments shall be used to improve perception, concentration, cognîtion, leaming or memory, like those occurring in particular in situations/diseases/syndromes such as: mild cognitive împairment, age-associated leaming and memory impairments, age-associated memory fosses, vascular dementia, craniocerebral trauma, stroke, dementîa occurring after strokes (post stroke dementia), post-traumatic dementia, general concentration impairments, concentration impairments in children with leaming and memory problems, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes, including Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with cortîcobasal degeneration, amyotropic latéral sclerosis (ALS), Huntington’s disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia, epilepsy, temporal lobe
-51 16302 epîlepsy, schizophrenia, schizophrenia (with dementia), Korsakoff s psychosis or cognitive impairment associated with dépréssion or bipolar disorder.
Another aspect of the présent invention may concem the treatment of a disease which is accessible by PDE9A modulation, in particular sleep disorders like insomnia or narcolepsy, bipolar disorder, metabolic syndrome, obesity, diabètes mellitus, including type 1 or type 2 diabètes, hyperglycemia, dyslipidemia, impaired glucose tolérance, or a disease of the testes, brain, small intestine, skeletal muscle, heart, lung, thymus or spleen.
Thus the medical aspect of the présent invention can be summarised in that it is considered that a compound according to formula (I) or (II) as herein defined, in particular the specifically defined species compounds is used as a médicament.
Such a médicament preferably is for the use in a method for the treatment of a CNS disease.
In an alternative use, the médicament is for the use in a therapeutic or prophylactic method, preferably a therapeutic method, for the treatment of a CNS disease, the treatment of which is accessible by the inhibition of PDE9.
In an alternative use, the médicament is for the use in a therapeutic or prophylactic method, preferably a therapeutic method, for the treatment of a disease that is accessible by the inhibition of PDE9, specifically PDE9A.
In the most preferred alternative use, the médicament is for the use in a therapeutic or prophylactic method, preferably a therapeutic method, for the treatment, amelioration and / or prévention of cognitive impairment being related to perception, concentration, cognition, leamîng or memory, preferably if such cognitive impairment is associated with a disease or condition as described in this section.
In an alternative use, the médicament is for the use in a therapeutic or prophylactic method, preferably a therapeutic method, for the treatment or the amelioration or prévention of cognitive impairment being related to age-associated leamîng and memory impainnents, ageassociated memory losses, vascular dementia, craniocerebral trauma, stroke, dementia occurring after strokes (post stroke dementia), post-traumatic dementia, general concentration împairments, concentration impairments in children with leamîng and memory problems,
-5216302
Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes, including Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyotropic latéral sclerosis (ALS), Huntington’s disease, multiple sclerosîs, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia, epilepsy, temporal lobe epilepsy, schizophrenia, schizophrenia (with dementia), Korsakoff s psychosis or cognitive impairment associated with dépréssion or bipolar disorder.
In an alternative use, the médicament is for the use in a therapeutic or prophylactic method, preferably a therapeutic method, for the treatment of Alzheimer’s disease, schizophrenia or cognitive impairment associated with Alzheimer’s disease or associated with schizophrenia.
In an alternative use, the médicament is for the use in a therapeutic or prophylactic method, preferably a therapeutic method, for the treatment of sleep disorders, bipolar disorder, metabolic syndrome, obesity, diabètes mellitus, hyperglycemia, dyslipidemia, impaired glucose tolérance, or a disease of the testes, brain, small intestine, skeletal muscle, heart, lung, thymus or spleen.
In a further aspect of the invention, the présent invention relates to the method of treatment or prévention of a condition or disease selected from the above listed groups of conditions and diseases, whereby the method comprises the administration of a therapeutically effective amount of a compound according to the invention in a human being in need thereof.
Another aspect of the invention concems the compounds of the inventions for use as a médicament in a therapeutic or prophylactic method, preferably a therapeutic method. If indicated the therapeutic method or the médicament is preferably for the treatment of a condition or a disease selected from the group of conditions or a diseases as outlined above in this section which is entitled “METHOD OF TREATMENT”.
PHARMACEUTICAL COMPOSITIONS
Médicaments for administration, which are also subject to the présent invention, comprise
- a compound according to the présent invention as a or the pharmaceutically active ingrédient in a therapeutically effective amount and
- a pharmaceutical carrier, x
-5316302
By therapeutically effective amount it is meant that if the médicament is applied via the appropriate regîmen adapted to the patient’s condition, the amount of said compound of formula (I) will be suffi oient to effectively treat, to prevent or to decelerate the progression of the corresponding disease, or otherwise to ameliorate the state of a patient suffering from such a disease. It may be the case that the therapeutically effective amount in a monotherapy will differ from the therapeutically effective amount in a combination therapy with another médicament.
The dose range of the compounds of general formula (I) applicable per day may be usually from 0.1 to 5000 mg, preferably from 0.1 to 1000 mg, preferably from 2 to 500 mg, more preferably from 5 to 250 mg, most preferably from 10 to 100 mg. A dosage unit (e.g. a tablet) preferably may contain between 2 and 250 mg, particularly preferably between 10 and 100 mg of the compounds according to the invention.
The actual pharmaceutically effective amount or therapeutic dosage will dépend on factors known by those skilled in the art such as âge, weight, gender or other condition of the patient, route of administration, severity of disease and the like.
The compounds according to the invention may be administered by oral, parentéral (intravenous, intramuscular etc.), intranasal, sublingual, inhalatîve, intrathecal, topical or rectal route. Suitable préparations for administering the compounds according to the présent invention include for example patches, tablets, capsules, pills, pellets, dragees, powders, troches, suppositories, liquid préparations such as solutions, suspensions, émulsions, drops, syrups, élixirs, or gaseous préparations such as aérosols, sprays and the like. The content of the pharmaceutically active compound(s) should be in the range from 0.05 to 90 wt.-%, preferably 0.1 to 50 wt.-% of the composition as a whole. Suitable tablets may be obtained, for example, by mixîng the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disîntegrants such as corn starch or alginic acid, binders such as starch or gélatine, lubricants such as magnésium stéarate or talc and/or agents for delayîng release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
- 5416302
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxîde or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Syrups or élixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanîllin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatîves such as p-hydroxybenzoates.
Solutions may be prepared in the usual way, e.g. with the addition of isotonie agents, preservatîves such as p-hydroxybenzoates or stabilisers such as alkali métal salts of ethylenediamine-tetra-acetic acid, optionally using emulsificrs and/or dispersants, while if water shall be used as diluent, for example, organic solvents may optionally be used as solubilisers or dissolving aids and the solutions maybe transferred into injection vials or ampoules or infusion bottles.
Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gélatine capsules.
Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the dérivatives thereof.
Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. éthanol or glycerol), carriers such as e.g. natural minerai powders (e.g. kaolins, clays, talc, chalk), synthetic minerai powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose), y
-5516302 emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnésium stéarate, talc, stearic acid and sodium lauryl sulphate).
For oral use the tablets may contain, in addition to the carriers specified, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various addîtional substances such as starch, preferably potato starch, gélatine and the like. Lubricants such as magnésium stéarate, sodium laurylsulphate and talc may also be used to produce the tablets. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the abovementioned excipients.
The dosage of the compounds according to the invention is naturally highly dépendent on the method of administration and the complaint which is being treated.
COMBINATIONS WITH OTHER ACTIVE SUBSTANCES
In another aspect the présent invention relates to a combination therapy in which a compound according to the présent invention is administered together with another active compound. Accordingly, the invention also refers to pharmaceutical formulations that provide such a combination of pharmaceutically active ingrédients, whereby one of which is a compound of the présent invention. Such combinations may be fixed dose combinations (the pharmaceutically active ingrédients that are to be combined are subject of the same pharmaceutical formulation) or free dose combinations (the pharmaceutically active ingrédients are in separate pharmaceutical formulations).
Consequently, a further aspect of the présent invention refers to a combination of each of the compounds of the présent invention, preferably at least one compound according to the présent invention, with another active compound for example selected from the group of beta-secretase inhibitors; gamma-secretase inhibitors; gamma-secretase modulators; amyloid aggregation inhibitors such as e.g. alzhemed; directly or indirectly acting neuroprotective and/or disease-modifying substances; anti-oxidants, such as e.g. vitamin E , ginko biloba or ginkolide; anti-inflammatory substances, such as e.g. Cox inhibitors, NSAIDs additionally or exclusively having AB (Abeta) lowering properties; HMG-CoA reductase inhibitors, such as statîns; acétylcholine esterase inhibitors, such as donepezil, rivastigmine, tacrine, z
-5616302 galantamine; NMDA receptor antagonists such as e.g, memantine; AMPA receptor agonists; AMPA receptor positive modulators, AMPkines, glycine transporter l inhibitors; monoamine receptor reuptake inhibitors; substances modulating the concentration or release of neurotransmitters; substances inducing the sécrétion of growth hormone such as ibutamoren mesylate and capromorelin; CB-l receptor antagonists or inverse agonists; antibiotics such as minocyclin or rifampicin; PDE1, PDE2, PDE4, PDE5 and / or PDE10 inhibitors, GABAA receptor inverse agonists; GABAA aipha5 receptor inverse agonists; GABAA receptor antagonists; nicotinic receptor agonists or partial agonists or positive modulators; alpha4beta2 nicotinic receptor agonists or partial agonists or positive modulators; alpha7 nicotinic receptor agonists or partial agonists; histamine receptor H3 antagonists; 5HT4 receptor agonists or partial agonists; 5-HT6 receptor antagonists; alpha2-adrenoreceptor antagonists, calcium antagonists; muscarinic receptor Ml agonists or partial agonists or positive modulators; muscarinic receptor M2 antagonists; muscarinic receptor M4 antagonists; metabotropic glutamate receptor 5 positive allosteric modulators; metabotropic glutamate receptor 2 antagonists; metabotropic glutamate receptor 2/3 agonists; metabotropic glutamate receptor 2 positive allosteric modulators and other substances that modulate receptors or enzymes in a manner such that the efficacy and/or safety of the compounds according to the invention is increased and/or unwanted side effects are reduced.
This invention further relates to pharmaceutical compositions contaîning one or more, preferably one active substance. At least one active substance is selected from the compounds according to the invention and/or the corresponding salts thereof. Preferably the composition comprises only one such active compound. In case of more than one active compound the other one can be selected fforn the aforementioned group of combination partners such as alzhemed, vitamin E, ginkolide, donepezil, rivastigmine, tacrine, galantamine, memantine, ibutamoren mesylate, capromorelin, minocyclin and/or rifampicin. Optionally the composition comprises further ingrédients such as inert carriers and/or diluents.
The compounds according to the invention may also be used în combination with immunothérapies such as e.g. active immunisation with Abeta or parts thereof or passive immunisation with humanised anti-Abeta antibodîes or antibody fragments for the treatment of the above mentioned diseases and conditions. s
- 5716302
The compounds according to the invention also may be combined with Dimebon.
The compounds according to the invention also may be combined with antidepressants like amitriptyline imipramine hydrochloride (TOFRANIL), imipramine maleate (SURMONTIL), lofepramine, desipramine (NORPRAMIN), doxepin (SINEQUAN, ZONALON), trimipramine (SURMONTIL).
Or the compounds according to the invention also may be combined with serotonin (5-HT) reuptake inhibitors such as alaproclate, citalopram (CELEXA, CIPRAMIL) escitalopram (LEXAPRO, CIPRALEX), clomipramine (ANAFRANIL), duloxetine (CYMBALTA), femoxetîne (MALEX1L), fenfluramine (PONDIMIN), norfenfluramine, fluoxetîne (PROZAC), fluvoxamine (LUVOX), indalpine, milnacipran (IXEL), paroxetine (PAXIL, SEROXAT), sertraline (ZOLOFT, LUSTRAL), trazodone (DESYREL, MOLIPAXIN), venlafaxine (EFFEXOR), zimelidine (NORMUD, ZELMID), bicîfadine, desvenlafaxine (PRISTIQ), brasofensme and tesofensine.
The combinations according to the présent invention may be provided simultaneously in one and the same dosage form, i.e. in form of a combination préparation, for example the two components may be incorporated in one tablet, e. g. in different layers of said tablet. The combination may be also provided separately, in form of a free combination, i.e. the compounds of the présent invention are provided in one dosage form and one or more of the above mentioned combination partners is provided in another dosage form. These two dosage forms may be equal dosage forms, for example a co-administration of two tablets, one containing a therapeutically effective amount of the compound of the présent invention and one containing a therapeutically effective amount of the above mentioned combination partner. It is also possible to combine different administration forms, if desired. Any type of suitable administration forms may be provided.
The compound according to the invention, or a physiologically acceptable sait thereof, in combination with another active substance may be used simultaneously or at staggered times, but particularly close together in time. If administered simultaneously, the two active substances are given to the patient together; if administered at staggered times the two active substances are given to the patient successively within a period of less than or equal to 12, particularly less than or equal to 6 hours. /
-5816302
The dosage or administration forms are not limited, in the context of the présent invention any suitable dosage form may be used. For example, the dosage forms may be selected from solid préparations such as patches, tablets, capsules, pills, pellets, dragees, powders, troches, suppositories, liquid préparations such as solutions, suspensions, émulsions, drops, syrups, élixirs, or gaseous préparations such as aérosols, sprays and the like.
The dosage forms are advantageously formulated in dosage units, each dosage unit being adapted to supply a single dose of each active component being présent. Depending from the administration route and dosage form the ingrédients are selected accordingly.
The dosage for the above-mentioned combination partners may be expediently l/5 of the normally recommended lowest dose up to l/l of the normally recommended dose.
The dosage forms are administered to the patient for example 1, 2, 3, or 4 times daily depending on the nature of the formulation. In case of retardîng or extended release formulations or other pharmaceutical formulations, the same may be applied differently (e.g. once weekly or monthly etc.). It is preferred that the compounds of the invention be administered either three or fewer times, more preferably once or twice daily.
EXAMPLES
PHARMACEUTICAL COMPOSITIONS
Examples which might illustrate possible pharmaceutical formulations, without being meant to be limitîng:
The term active substance dénotés one or more compounds according to the invention including the salts thereof. In the case of one of the aforementioned combinations with one or more other active substances the term active substance may also include the additional active substances.
Example A ✓
-5916302
Tablets containing 100 mg of active substance
Composition: tabiet
active substance | 100.0 mg |
lactose | 80.0 mg |
corn starch | 34.0 mg |
polyvinylpyrrolîdone | 4.0 mg |
magnésium stéarate | 2.0 mg |
220.0 mg |
Example B
Tablets containing 150 mg of active substance
Composition: tabiet
active substance | 150.0 mg |
powdered lactose corn starch | 89.0 mg 40.0 mg |
colloïdal silica | 10.0 mg |
polyvinylpyrrolîdone magnésium stéarate | 10.0 mg 1.0 mg 300.0 mg |
Examnle C
Hard gélatine capsules containing 150 mg of active substance
active substance | 150.0 mg |
lactose | 87.0 mg |
corn starch (dried) | 80.0 mg |
-6016302
magnésium stéarate | 3.0 mg 320.0 mg |
Example D
Composition: suppository
active substance | 150.0 mg |
polyethyleneglycol 1500 polyethyleneglycol 6000 polyoxyethylene sorbitan monostearate | 550.0 mg 460.0 mg 840.0 mg |
2000.0 mg
Example E
Composition: ampoules containing 10 mg active substance
active substance 0.01 N hydrochloric acid q.s. double-distilled water ad | 10.0 mg 2.0 mL |
Example F
Composition: ampoules containing 50 mg of active substance active substance 50.0 mg
0.01 N hydrochloric acid q.s.
double-distîlled water ad 10.0 mL
The préparation of any the above mentioned formulations can be done following standard procedures. /
-61 16302
BIOLOGICAL ASSAY
The in-vitro effect of the compounds of the invention can be shown with the following biological assays.
PDE9A2 assay protocol:
The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Healthcare, former Amersham Biosciences, product number: TRKQ 7100).
As enzyme source, lysate (PBS with 1 % Triton X-100 supplemented with protease inhibitors, cell débris removed by centrifugation at 13.000 rpm for 30 min) of SF 9 cell expressing the human PDE9A2 was used. The total protein amount included in the assay varied upon infection and production efficacy of the SF9 cells and lay in the range of 0.1 100 ng.
In general, the assay conditions were as follows:
• total assay volume: 40 microlitre • protein amount: 0.1-50 ng • substrate concentration (cGMP): 20 nanomolar; ~1 mCi/1 • incubation time: 60 min at room température • final DMSO concentration: 0.2 -1 %
The assays were run in 384-well format. The test reagents as well as the enzyme and the substrate were diluted in assay buffer. The assay buffer contained 50 mM Tris, 8.3 mM MgC12, 1.7 mM EGTA, 0.1 % BSA, 0.05 % Tween 20; the pH of assay buffer was adjusted to 7.5. The reaction was stopped by applying a PDE9 spécifie inhîbîtor (e.g. compounds according to WO 2004/099210 or WO 2004/099211, like one of the enantiomeres of example 37, e.g. 1 -(2-ChI orophenyl)-6-[(2R)-3,3,3-tri fiuoro-2-methyl-propyl]-1,5-dihydro-4Hpyrazolo[3,4-d]pyrimidine-4-one) in excess.
References: x
-6216302
Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M. Characterization of the first potent and sélective PDE9 inhibitor using a cGMP reporter cell line. Molecular Pharmacology. 2005 Dec;68(6): 1775-81.
van der Staay FJ, Rutten K, Bârfacker L, Devry J, Erb C, Heckroth H, Karthaus D, Tersteegen A, van Kampen M, Blokland A, Prickaerts J, Reymann KG, Schroder UH, Hendrix M. The novel sélective PDE9 inhibitor BAY 73-6691 improves leaming and memory in rodents. Neuropharmacology. 2008 Oct;55(5):908-18.
PDE1C assay protocol:
The assay was run in an analogous manner to the PDE9A2 assay, with the following différences: instead of PDE9A2, PDE1C was used and the assay buffer contained in addition 50 nM Calmodulin, 3 mM CaCU. The reaction can be stopped by applying the same inhibitor than the one that is outlined above (l-(2-Chlorophenyl)-6-[(2R)-3,3,3-trifluoro-2-methylpropyl]-l,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one).
Détermination of Κ\η*.
IC50 can be caiculated with GraphPadPrism or other suited software setting the positive control as 100 and the négative control as 0. For calculation of IC5o dilutions of the test compounds (substrates) are to be selected and tested following the aforementioned protocol.
Data
In the following IC50 values for PDE9A2 inhibition [nanomolar (nM)] illustrate that the compounds according to the présent invention inhibit PDE9, specifically PDE9A2. This évidences that the compounds provide useful pharmacological properties. The examples are not meant to be limiting.
The table also provides selectivity values (Selectivity) that show a preference of the compounds for PDE9A versus PDE1C. Selectivity is the ratio (IC50 for PDE1C inhibition [nanomolar (nM)]) / (IC50 for PDE9A2 inhibition [nanomolar (nM)]). z-6316302
The example numbers refer to the final examples as outlined in the section Exemplary embodiments and as defined by the above compound family table (embodiment 25).
Ail data can be measured according to the procedure described herein. The définition enantîomer l or enantiomer 2 is related to the elution orders of enantiomers in chiral SFC and 5 chiral HPLC.
Compound family | Example No. | IC50 PDE9A2 [nanomolar] | Selectivity |
A | 1* | 450 | 3 |
B | 2* | 5 | 143 |
C | 3* | 23 | 34 |
D | 4* | 242 | 22 |
E | 5* | 60 | 14 |
F | 6* | 58 | 15 |
G1 | 7* | 31 | 15 |
G2 | 8* | 85 | 63 |
Hl | g* | 19 | 46 |
H2 | 10* | 13 | 120 |
I | 11* | 233 | >43 |
J | 12* | 80 | 38 |
K | 13* | Ί | 328 |
K | 14 (enantiomer 1) | 473 | 4,3 |
K | 15 (enantiomer 2) | 4 | 424 |
L | 16* | 5 | 245 |
M | 17* | 16 | 78 |
M | 18 (enantiomer 1 ) | 5 | 255 |
M | 19 (enantiomer 2) | 1345 | 0.61 |
N | 20* | 31 | 68 |
0 | 21* | 433 | 10 |
P | 22* | 21 | 49 |
Q | 23 | 23 | 187 |
Q | 24 (enantiomer 1) | 218 | 8.9 |
-6416302
Compound famîly | Example No. | IC5o PDE9A2 [nanomolar] | Selectivity |
Q | 25 (enantiomer 2) | 7 | 197 |
R | 29* | 11 | 117 |
R | 30 (enantiomer 1) | 304 | 4.95 |
R | 31 (enantiomer 2) | 7 | 186 |
S | 32* | 7 | 117 |
S | 33 (enantiomer 1) | 4 | 181 |
S | 34 (enantiomer 2) | 388 | 1.68 |
T | 26* | 32 | >400 |
T | 27 (enantiomer 1) | 11 | 250 |
T | 28 (enantiomer 2) | 360 | 7 |
* trans racemic mixture
In-vivo effect:
It is believed that the positive in-vitro efficacy results of the compounds of the présent invention translate in positive in-vivo efficacy.
The in-vivo effect of the compounds of this invention can be tested in the Novel Object Récognition test according to the procedure of Prickaerts et al. (Neuroscience 2002,113, 351-361), the social récognition test or the T-maze spontaneous alternation test according to 10 the procedures described by van der Staay et al. (Neuropharmacology 2008, 55, 908-918).
For further information conceming biological testing one is also referred to these two citations.
Besides the inhibition property toward the target PDE9, compounds according to the présent invention may provide further advantageous pharmacokinetic properties.
E.g. compounds according to the invention may show one or more advantages in the area of safety, balanced metabolism, low risk of causing drug - drug interaction and/or balanced clearance. /
-6516302
Compounds also might show one or more additional or alternative advantages in the area of bioavailability, high fraction absorbed, blood brain transport properties, a favourable (e.g. high mean) résidence time (mrt), favourable exposure in the effect compartment and so on.
CHEMICAL MANUFACTURE
Abbreviations:
Burgess-reagent (methox ycarbonylsulfamoyl)-tri ethyl ammonium-N-betain
Lawesson’s reagent 2,4-bis-(4-methoxy-phenyl)-[ l ,3,2,4]dithiadiphosphetane 2,4-
APCI | disulfide Atmospheric pressure chemical ionization |
ACN | acetonitrile |
CDI | 1,1 ’-carbonyldiîmidazole |
DEA | diethylamîne |
DIPEA | diisopropylethylamine |
DME | 1,2-dimethoxyethane |
DMF | dimethylformamide |
ESI | electrospray ionization (in MS) |
EtOH | éthanol |
Exp. | example |
h | hour(s) |
HATU | O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium |
HPLC | hexafluorophosphate high performance liquid chromatography |
HPLC-MS | coupled high performance liquid chromatography-mass spectrometry |
M | molar (mol/L) |
MeOH | methanol |
min | minutes |
MS | mass spectrometry |
NMP | l-methyl-2-pyrrolidinone ' |
-6616302
R* | rétention time (in HPLC) |
SFC | supercrtîcial fluid chromatography |
TBTU | O-(benzotriazol-l -yl)-N,N,N',N -tetramethyluronium tetrafluoroborate |
TFA | trifluoroacetic acid |
THF | tetrahydrofuran |
TLC | thin-layer chromatography |
LC-MS methods:
Method 1
MS apparatus type: Waters Micromass ZQ; HPLC apparatus type: Waters Alliance 2695, Waters 2996 diode array detector; column: Varian Microsorb 100 Cl8, 30 x 4.6 mm, 3.0 μιη; eluent A: water + 0.13 % TFA, eluent B: ACN; gradient: 0.0 min 5 % B —> 0.18 min 5 % B -> 2.0 min 98 % B -> 2.2 min 98 % B -> 2.3 min 5 % B —> 2.5 min 5 % B; flow rate: 3.5 mL/min; UV détection: 210-380 nm.
Method 2
MS apparatus type: Waters Micromass ZQ; HPLC apparatus type: Waters Alliance 2695, Waters 2996 diode array detector; column: Varian Microsorb 100 Cl8, 30 x 4.6 mm, 3.0 μιη; eluent A: water + 0.13 % TFA, eluent B: MeOH; gradient: 0.0 min 5 % B -> 0.35 min 5 % B —> 3.95 min 100 % B -> 4.45 min 100 % B -> 4.55 min 5 % B > 4.9 min 5 % B; flow rate: 2.4 mL/min; UV détection: 210-380 nm.
Method 3
MS apparatus type: Waters Micromass ZQ; HPLC apparatus type: Waters Alliance 2695, Waters 2996 diode array detector; column: Varian Microsorb Cl8, 20 x 4.6 mm, 5.0 μιη; eluent A: water + 0.15 % TFA, eluent B: MeOH; gradient: 0.0 min 5 % B —» 0.25 min 5 % B -> 1.90 min 100 % B > 2,05 min 100 % B -> 2.15 min 5 % B —> 2.25 min 5 % B; flow rate:
5.2 mL/min; UV détection: 210-400 nm. /
-6716302
Method 1E hydro
Instrument: LC/MS ThermoFinnigan. Hplc Surveyor DAD, MSQ Quadrupole; column: Synergi Hydro-RP80A, 4 um, 4.60 x 100 mm; eluent A: 90% water + 10% acetonitrile + ammonium formate 10 mM; eluent B = ACN 90%+10% H2O + NH4COOH 10 mM; gradient: A (100) for 1.5 min, then to B (100) in 10 min for 1.5 min; flow rate: 1.2 mL/min; UV Détection: 254nm; Ion source: APCI.
Chiral SFC methods:
Method 4
SFC apparatus type: Berger “Analytix”; column: Daicel IC, 250 mm x 4.6 mm, 5.0 μτη; eluent: CO2 / 25 % MeOH / 0.2 % DEA (isocratic); flow rate: 4.0 mL/min, 10 min; température: 40°C; (JV détection: 210/220/254 nm.
Method 5
SFC apparatus type: Berger “Analytix”; column: Daicel ADH, 250 mm x 4.6 mm, 5.0 μτη; eluent: CO2 / 25 % MeOH / 0.2 % DEA (isocratic); flow rate: 4.0 mL/min, 10 min; température: 40°C; UV détection: 210/220/254 nm.
Chiral HPLC methods:
Method 6:
HPLC apparatus type: Agilent 1100; column: Daicel chiralcel OJ-H, 250 mm x 4.6 mm, 5.0 μην; eluent: hexane/EtOH80:20; flow rate: 1 mL/min, Température: 25°C; UV Détection: variable (200- 500 nm).
Method 6.1:
HPLC apparatus type: Agilent 1100; column: Daicel chiralcel OJ-H, 250 mm x 4.6 mm, 5.0 pm,; eluent: hexane/EtOH 85:15; flow rate: 1 mL/min, Température: 25°C; UV Détection: variable (200- 500 nm).
Method 7: z
-6816302
HPLC apparatus type: Agilent 1100; column: Chiralpak AD-H, 250 mm x 4.6 mm, 5.0 pm,; eluent: hexane/isopropanol 80:20; flow rate: l mL/min, Température: 25°C; UV Détection: variable (200- 500 nm).
HPLC apparatus type: Agilent 1100; column: Chiralpak AD-H, 250 mm x 4.6 mm, 5.0 pm,; eluent: hexane/isopropanol 80:20; flow rate: 1 mL/min, Température: 25°C; UV Détection: variable (200- 500 nm).
Microwave heating:
• Discover® CEM instruments, equipped with 10 and 35 mL vessels;
• Biotage Initiator Sîxty.
General comment concerning the présentation of the structures
Compounds with stereogenic centre(s): The structures depicted in the experimental section below will not necessarily show ail the stereochemical possibilities of the compounds but only one. However, in such cases a term like “trans - racemic mixture” or “cîs-racemic mixture” is added next to the depicted structure in order to indicate the other stereochemical options.
An example is given below. The presented structural formula is ,,.Χχ trans - racemic mixture
The added term “trans-racemic mixture” points to the second stereochemical option:
-6916302 _χΧχ γν
Thus, the manufacturée! compound is a mixture of
This principle applies to other depicted structures as well.
Starting compounds:
Example 1A (trans - racemic mixture)
trans - racemic mixture
2.00 g (13.9 mmol) trans-cyclobutan-l,2-dicarboxylîc acid were mixed with 16 mL EtOH at
0°C and 2.21 mL (30.5 mmol) thionylchloride were slowly added. The mixture was allowed to warm to room température and stirred for lh. The solvent was removed under reduced pressure and the product was filtered through a pad of activated basic alumina. 2.71 g (98 %) of the product were obtained.
HPLC-MS (Method 1): Rt = L34 min
MS (ESI pos): m/z = 201 (M+H)+
The following example was synthesized in analogy to the préparation of Example 1 A, using the corresponding dîaeid as starting material.
Example | structure | starting material | Rt [min] | MS (ESI pos, m/z) |
-7016302
Example 2A (racemic mixture)
8.00 g (89.7 mmol) 2-amino-propîonic acid were mixed with 88.0 mL (0.93 mol) acetic anhydride and 88.0 mL pyridine. The reaction mixture was stirred at 100°C for 135 min. The solvent was removed under reduced pressure. Toluene was added to the residue and the solvent was removed under reduced pressure, then 204 mL (816 mmol) HCl (4 M aqueous solution) was added and the mixture was refluxed for 3h. The solvent was removed under reduced pressure. 1-Butanol (20 mL) was added to the residue and the solvent was removed under reduced pressure. 11.6 g of the title compound were obtained as hydrochloride sait. MS (ESI pos): m/z = 88 (M+H)+
Example 3A (trans - racemic mixture)
1.00 g (4.09 mmol) 5-Amino-l-(4,4-difluoro-cyclohexyl)-lH-pyrazole-4-carboxylîc acid amide (see PCT patent application WO 2010/026214, example 8A) was mixed with 15 mL of /
-71 16302 anhydrous EtOH, 2.46 g (12.3 mmol) of Example IA and 0.66 g (16.4 mmol) of sodium hydride (60 % suspension în minerai oil) were added. The reaction mixture was heated to 140°C for 30 min in a microwave oven. The mixture was cooled to room température and sodium hydroxide solution (4 M aqueous solution) was added. The solvent was removed under reduced pressure. The residue was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH). 0.70 g (49 %) ofthe product were obtained.
HPLC-MS (Method 1 ): R, =-1.24 min
MS (ESI pos): m/z = 353 (M+H)+
The following examples were synthesized in analogy to the préparation of Example 3A, using 10 the corresponding amide and ester as starting materials (for starting materials it is referred to
PCT patent publications WO 2010/026214, WO 2009/121919 and WO 2004/09921 ).
Example | structure | starting material: amide | starting material: ester | R. [min] | MS (ESI pos, m/z) |
Exp. 3 B (trans racemic mixture) | '-'O | 5-amino-l(tetrahydropyran-4-yl)-lHpyrazole-4carboxylic acid amide (see WO 2009/121919, example 11 B) | Exp. IB | 1.07 (Meth od 3) | 319 (M+H)+ |
Exp. 3C (trans racemic mixture) | η°Ύ hO0n x k | 5-amino-l-(4methyl-pyridin3-yl)-lHpyrazole-4carboxylic acid amide (see WO 2004/099211, example 3 5A) | Exp. IA | 0.81 (Meth od 1): | 326 (M+H)+ |
-7216302
0.200 g (0.568 mmol) Example 3A were mixed with 0.157 mL (1.14 mmol) triethylamine and 5 mL DMF. To the mixture were added 0.237 g (0.624 mmol) HATU, then the réaction mixture was stirred at room température for 10 min. To the mixture were added 0.042 g (0.568 mmol) acetîc acid hydrazide and the reaction mixture was stirred at room température for lh. The mixture was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH). 30 mg of the product were obtained.
HPLC-MS (Method 1): Rt = 1.03 min
MS (ESI pos): m/z = 409 (M+H)+
Example 5A (trans - racemic mixture)
trans - racemic mixture
0.150 g (0.426 mmol) of Example 3A were mixed with 2 mL THF. The mixture was cooled to 0°C and 0.036 mL (0.426 mmol) oxalylchloride and one drop of DMF were added. The reaction mixture was stirred at 0°C for lh. To the reaction mixture were added 2 mL ACN and 0.426 mL (0.851 mmol) trimethylsilyldiazomethane (2 M in hexane). The mixture was stirred for 2h, then 0.213 mL HCl (4 M in dioxane) was slowly added. The reaction was /
-73 16302 stirred for 3h. To the mixture were added ethylacetate and saturated aqueous sodium hydrogen carbonate solution. The organic layer was washed with water and brine and dried over sodium sulfate. The solvents were partially evaporated until volume of approximately 2 mL was reached. The mixture was taken to the next step without further purification.
HPLC-MS (Method l): Rt = 1.40 min
MS (ESI pos): m/z = 385/387 (Cl)
The following example was synthesized in analogy to the préparation of Example 5A, using the corresponding acid as starting material.
Example | structure | starting material | R, [min] | MS (ESI pos, m/z) |
Exp. 5B trans- racemic mixture | T b 0 Cl o | Exp. 3 B | I.l2 (Method 1) | 351/353 (Cl) |
Example 6A (trans - mixture of stereoisomers)
-7416302
0.200 g (0.628 mmol) of Example 3B were mixed with l mL DMF. 0.261 mL (1.89 mmol) triethylamine and 0.222 g (0.691 mmol) of TBTU were added. The reaction mixture was stirred at room température for 10 min. Then 0.078 g (0.628 mmol) of Example 2A was added and the mixture was stirred at room température for lh. The mixture was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH). 190 mg of the product were obtained.
HPLC-MS (Method 3): Rt = 1.03 min
MS (ESI pos): m/z = 388 (M+H)+
0.200 g (0.628 mmol) of Example 3B were mixed with 1 mL DMF. 0.174 mL ( 1.26 mmol) triethylamine and 0.222 g (0.691 mmol) of TBTU were added. The reaction mixture was stirred at room température for 10 min. Then 0.066 g (0.628 mmol) 2,2-dimethoxyethylamine was added and the mixture was stirred at room température for lh. Then HCl (2 M aqueous solution) was added and the mixture was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH). The residue was mixed with 5 mL acetone and 1 mL HCl (2 M aqueous solution) and stirred overnight under nitrogen. Then the mixture was extracted with DCM. The organic layer was evaporated and purified by préparative HPLC (eluent A: water +0.13 % TFA, eluent B: MeOH). 170 mg of the product was obtained.
HPLC-MS (Method 3): R, = 1.01 min
MS (ESI pos): m/z = 360 (M+H)+
Example 8A (trans - mixture of stereoisomers) s
-75 16302
0.200 g (0.568 mmol) of Example 3A was mixed with l.O mL DMF. 0.432 mL (2.84 mmol) DIPEA and 0.200 g (0.624 mmol) TBTU were added. The reaction mixture was stirred at room température for 10 min. Then 0.140 g ( l. 14 mmol) of Example 2A were added and the mixture was stirred at room température for 2h. The mixture was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH). 70 mg (29 %) of the product was obtained.
HPLC-MS (Method l): Rt = 1.23 min
MS (ESI pos): m/z = 422 (M+H)+
The following examples were synthesized in analogy to the préparation of Example 8A, using the corresponding nucleophiles as starting materials..
Example | structure | starting material | Rt [min] | MS (ESI pos, m/z) |
Exp. 8B trans - racemic mixture | A z° | H hydrochloride | 1.31 (method n | 396 (M+H)+ |
-7616302
Exp. 8C trans - mixture of stereoisomers | Q F | x'X^NH, HO | 410 (M+H)+ | |
Exp. 8D trans - mixture of stereoisomers | Q F | X». | 1.12 (method 1) | 410 (M+H)+ |
Exp. 8E trans - racemic mixture | GcV Q F h | hydrazine hydrate | 0.99 (method 1) | 367 (M+H)+ |
Example 9A (trans - racemic mixture)
trans - racemic mixture
0.182 g (0.430 mmol) Dess-Martin periodinane were mixed with 2.5 mL DCM. 0.160 g (0.391 mmol) Example 8D in 2.5 mL DCM was added at room température. The reaction /
-7716302 mixture stirred at room température for 30 min and at 30°C for 30 min. To the mixture were added 10 mL sodium thiosulfate solution (10 % in water) and 10 mL saturated sodium hydrogen carbonate solution and the mixture was stirred for 20 min. The organic layer was separated and the aqueous layer was extracted with DCM. The organic layer was washed with saturated sodium hydrogen carbonate solution, dried and evaporated. 93 mg (58 %) of the product were obtained.
HPLC-MS (Method 1): Rt = 1.18 min
MS (ESI pos): m/z - 408 (M+H)+
The following example was synthesized in analogy to the préparation of Example 9A, using the corresponding alcohol as starting material.
Example | structure | starting material |
Exp. 9B trans - mixture of stereoisomers | VF Q F | Exp. 8C |
Example 10A (trans - mixture of stereoisomers)
0.450 g of Example 3C was mixed with 3.5 mL DMF and 0.273 g (2.21 mmol) Example 2A.
1.00 mL (6.64 mmol) DIPEA and 0.390 g (1.22 mmol) TBTU were added and the mixture
-7816302 was stirred for lh. The mixture was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH). 360 mg (83 %) of the product was obtained.
HPLC-MS (Method 1): Rt = 0.85 min
MS (ESI pos): m/z = 395 (M+H)+
Example 11A (trans - racemic mixture) trans - racemic mixture
300 mg (1.23 mmol) of 5-amino-l-(4,4-difluoro-cyclohexyl)-lH-pyrazole-4-carboxylic acid amide (see WO 2010/026214, example 8A) were mixed with 4 mL anhydrous EtOH, 326 mg (3.07 mmol) trans-cyclobutane-l,2-dicarbonitrile and 0.197 g (4.91 mmol) of sodium hydride (60 % suspension în minerai oil) under nitrogen. The reaction mixture was heated to 140°C for 45 min in a microwave oven. The solvent was removed under reduced pressure. The residue was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH).
210mg(51 %)ofthe title compound were obtained.
HPLC-MS (Method 3): Rt = 1.19 min
MS (ESI pos): m/z = 334 (M+H)+
Example 1 IB (trans - racemic mixture) '
-7916302
trans - racemic mixture
To a solution of 0.8 g (3.805 mmol) of 5-amino-l-(tetrahydro-pyran-4-yl)-l-H-pyrazole-4carboxylic acid amide (see PCT patent application WO2010/026214) in 8 mL anhydrous EtOH , 0.457 g (19.6 mmol) of sodium hydride (60 % suspension in minerai oil) were added 5 at room température under nitrogen. After 1 h under stirring, 1.2g (11.42mmol) of transcyclobutane-l,2-dicarbonîtrile were added and the reaction mixture was heated to 140°C for 45 min in a microwave oven. The solvent was removed under reduced pressure. The residue was dissolved in DCM, water was added and phases were separated. Organic layers were dried over sodium sulphate and evaporated under reduced pressure. The crude was purified 10 by flash cromatography (Cy/EtOAc from 80/20 to 100%) to obtain the title compound as yellow solid. (0.64g, 55%)
HPLC-MS(MethodlEh):Rt=6.21min
MS (APCI): m/z = 300 (M+H)+
trans - racemic mixture s
-8016302
To a solution of 0.85 g (3.91 mmol) of 5-amino-l-(4-methyl-pyridin-3-yl)-lH-pyrazole-4carboxylic acid amide (see PCT patent application WO 2004/09921) in 10 mL anhydrous EtOH , 0.47 g (11.74 mmol) of sodium hydride (60 % suspension in minerai oil) were added at room température under nitrogen. After 1 h under stirring, 1.28g (11.74 mmol) of transcyclobutane-l,2-dicarbonitrile were added and the reaction mixture was heated to I40°C for 45 min in a microwave oven. The reaction mixture was then loaded on SCX cartridge, ammonia fractions were collected and evaporated and the residue was purified by flash cromatography ( DCM/MeOH 90:10) to obtain the title compound as white solid. (0.63g, 52%).
HPLC-MS (Method lEh): R( = 5.92 min
MS (APCI pos): m/z = 307 (M+H)+
Example 12A (trans - racemic mixture)
HN trans - racemic mixture
190 mg (0.570 mmol) of Example 11A were mixed with 0.281 mL toluene and 0.093 mL (2.30 mmol) anhydrous MeOH. 0.103 mL (1.45 mmol) acetylchloride were added slowly at 0°C. The mixture was stirred at room température for 12h. The solvent was removed under reduced pressure. To the residue 0.5 mL MeOH were added. Then 0.407 mL (2.85 mmol) ammonia (7 M in MeOH) were added at 0°C and the mixture was allowed to warm to room température. After 30 min the reaction mixture was treated with water and the pH was adjusted to pH=l by addition of TFA. The mixture was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH) yielding 110 mg (42 %) of the product were as trifluoroacetic acid sait, ,
-81 16302
HPLC-MS (Method 3): R, = 1.04 min
MS (ESI pos): m/z = 351 (M+H)+
trans - racemic mixture
To a mixture of dry EtOH (5mL) and dry CHC13 (5mL) cooled at 0°C, acetylchloride (2.27mL, 30.82mmol) was added slowly and mixture left under stirring for 20min. 0°C. A solution of Example 1 IB (0.410g, 1.027mmol) in dry CHC13 (5mL) was added dropwise and the mixture stirred at room température overnight. Solvents were evaporated under reduced 10 pressure, residue dissolved in dry EtOH (5mL) and 6.4mL of a 7.0M solution of ammonia in
MeOH (30.82mmol) were added. The mixture was stirred at room température for 12h. The solvent was removed under reduced pressure. The final product was obtained as hydrochloride and used for the next step wîthout further purification. (0.37g, content 50% estimated by HPLC-MS).
HPLC-MS (Method lEh): Rt = 5.38 min
MS (APCI pos): m/z = 317 (M+H)+
Example 12 C (trans - racemic mixture)
-8216302
trans - racemic mixture
To a mixture of dry EtOH (4mL) and dry CHCl3 (lOmL) cooled at 0°C, acetylchloride (4.38 mL, 61.7 mmol) was added slowly and mixture left under stirring for 20min. 0°C. A solution of Example 11C (0.63g, 2.057 mmol) in dry CHCI3 (5mL) was added dropwise and the mixture stirred at room température overnight. Solvents were evaporated under reduced pressure, residue dissolved in dry MeOH (lOmL) and 10.3 mL of a 7.0M solution of ammonia in MeOH (72 mmol) were added. The mixture was stirred at room température for 12h. The solvent was removed under reduced pressure. The final product, obtained as hydrochloride sait, was used as such in the next step without further purification. (0.85g, content 84%, estimated by 1 H-NMR).
HPLC-MS (Method lEh): Rt = 5.15 min
MS (APC1 pos): m/z = 324 (M+H)+
Example 13A (trans - racemic mixture)
To a solution of 1.6 g (10.24 mmol) of 2-acetyl-cyclobutanecarboxylic acid methyl ester (prepared as described in J. Med. Chem, 25, 109, 1982) in dry EtOH (12mL), propargylamine (1.4mL, 20.4mmmol) was added followed by 0.122g (0.307mmol) of sodium gold trichloride. The reaction mixture was heated to 140°C for 45 min in a microwave oven, solid was filtered and the organic evaporated. Crude was purified by flash cromatography (Cy/EtOAc 70:30) to obtaîn the title compound as yellow green oil. (0.18g, 9.2%). '
- 83 16302
HPLC-MS (Method 1 Eh): Rt = 0.87 min
MS (APCI pos): m/z = 192 (M+H)+
Exemplary embodiments
Example 1 (trans - racemic mixture)
trans - racemic mixture
22.0 mg (0.306 mmol) of propan-2-one oxime were mixed with 2 mL anhydrous THF and 0.471 mL (1.22 mmol) n-butyllithium (2.6 mol/L in toluène) was added carefully to the mixture. The reaction mixture was stirred at room température for 30 min. 0.110 g (0.278 mmol) of Example 8B in 1 mL anhydrous THF were carefully added during 10 min. After 30 min the reaction mixture was added to a mixture of 0.28 mL H2SO4 and 4 mL THF/water (4:1). The mixture was refluxed for 1.5h. Saturated aqueous sodium hydrogen carbonate solution was added and extracted with ethylacetate. The organic layer was dried and the solvents were evaporated. The residue was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH). 8 mg(8 %) of the product were obtained.
HPLC-MS (Method 1): Rt = 1.40 min
MS (ESI pos): m/z = 390 (M+H)+
Examnle 2 (trans - racemic mixture) x
-8416302
0.190 g of Example 6A were mixed with 3 mL DME and 0.273 g (1.14 mmol) Burgess reagent. The reaction mixture was heated to 130°C for 1 h in a microwave oven. The solvent was evaporated and the residue purifîed by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH). 70 mg (55 %) of the product were obtained.
HPLC-MS (Method 1): Rt = 1.11 min
MS (ESI pos): m/z = 370 (M+H)+
The following examples were synthesized in analogy to the préparation of Example 2, using the corresponding amides as starting materials.
Example | structure | starting material | R, [min] | MS (ESI pos, m/z) |
Exp. 3 transracemic mixture | A X-, AÇQ Q | Exp. 7A | 1.17 (Method 3) | 342 (M+H)+ |
-85 16302
Exp. 4 trans racemic mixture | î N=v Xj3 | Exp. 4A | 1.20 (Method 1 ) | 391 (M+H)+ |
Exp. 5 transracemic mixture | î'c- v / | Exp. 8A | 1.38 (method 1) | 404 (M+H)+ |
Exp. 6 transracemic mixture | XJ> F | Exp. 9A | 1.37 (method 1) | 390 (M+H)+ |
Exp. 7 trans racemic mixture | Exp. 9B | 1.42 (method 3) | 390 (M+H)+ |
-8616302
Example 9 (trans - racemic mixture)
trans - racemic mixture
To a solution of Example 5A, synthesized starting from 0.426 mmol of Example 3A as described above, was added dropwise 0.062 g (0.832 mmol) thioacetamide in 2 mL EtOH. The reaction mixture was stirred ovemight. The mixture was purified by préparative HPLC (eluent A: water + O.l3 % TFA, eluent B: MeOH). 62 mg of the title compound were obtained.
HPLC-MS (Method 1): Rt = 1.37 min
MS (ESI pos): m/z = 406 (M+H)+
The following examples were synthesized in analogy to the préparation of Example 9, using the corresponding starting materials.
Example | structure | starting material: nucleophile | starting material: chloroketon | R, [min] | MS (ESI pos, |
- 8716302
m/z) | |||||
Exp. 10 trans racemic mixture | IjO1 h N A | thioacetamide | Exp. 5B | 1.21 (Method 3) | 372 (M+H)+ |
Exp. 11 trans racemic mixture | Ά, x | 1,1-dîmethylthiourea | Exp. 5A | 1.15 (Method 3) | 435 (M+H)+ |
Exp. 12 trans racemic mixture | H| JPN V À | thiourea | Exp. 5A | 1.15 (Method 3) | 407 (M+H)+ |
Example 13 (trans - racemic mixture)
Z
-8816302
ÎOO mg (0.215 mmol) of Example 12A were mixed with 1.00 mL(6.07 mmol) 1,1,3,3tetramethoxypropane. The reaction mixture was heated to 175°C for Ih using a microwave oven. The reaction mixture was treated with DCM/MeOH and one drop of triethylamine. The solvents were removed under reduced pressure. The mixture was purified by préparative
HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH) yielding 45 mg (54 %) of the title compound.
HPLC-MS (Method 3): Rt = 1-36 min
MS (ESI pos): m/z = 387 (M+H)+
The enantiomers of the title compound were separated by HPLC using a chiral stationary phase.
Method for enantioseparation:
HPLC apparatus type: Berger Minigram; column: Daicel IC, 5.0 pm, 250 mm x 10 mm; method: eluent CO? / 30 % MeOH / 0.2 % DEA (isocratic); flow rate: 10 mL/min, Température: 40°C; pressure: 100 bar; UV Détection: 210 nm
Example | structure | R, [min] |
Exp. 14 trans enantiomer 1 | t h | 3.15 (Method 4) |
-8916302
The following example was synthesized in analogy to the préparation of Example 13, using the corresponding dialdehydediacetal as starting material.
Example | structure | starting material | Rt [min] | MS (ESI pos, m/z) |
Exp. 16 trans racemic mixture | h£jCn M | 1,1,3,3tetraethoxy-2methylpropane | 1.42 (Method 3) | 401 (M+H)+ |
Example 17 (trans - racemic mixture)
-9016302
176 mg (0.431 mmol) of Example 4A were mixed with 3 mL THF and 122 mg (0.302 mmol) Lawesson’s reagent at room température. Then the mixture was stirred for 6h at 60°C. The reaction mixture was treated with water and diluted with DCM. The mixture was filtered over basic alumia and eluted with DCM und EtOH. The solvents were removed under reduced pressure. The residue was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH). 45 mg (26 %) of the product were obtaîned.
HPLC-MS (Method 3): Rt = 1.37 min
MS (ESI pos): m/z = 407 (M+H)+
The enantiomers of the tîtle compound were seperated by HPLC using a chiral stationary phase.
Method for enantioseparation:
HPLC apparatus type: Berger Minigram; column: Daicel ADH, 5.0 pm, 250 mm x 10 mm; method: eluent CO2 / 30 % MeOH / 0.2 % DEA (isocratic); flow rate: 10 mL/min,
Température: 40°C; pressure: 100 bar; UV Détection: 210 nm
Example | structure | R, [min] |
Exp. 18 trans enantiomer 1 (S,S) | Q | 2.47 (Method 5) |
-91 16302
2.96 (Method
5)
Single crystals of example 19 hâve been prepared by recrystallisation from ethylacetate and subjected to X-ray crystal analysis. The data allowed to détermine the absolute configuration of example 19 to be (R,R).
Experimental: Data collection and réduction: Data collected on Satum 944 CCD mounted on AFC11K goniometer, Radiation: Cu Ka from RU200 rotating anode and RIGAKU
VARIMAX optics, Température: 100K.
Suinmary of data collection statistîcs
Spacegroup Unit cell dimensions | P2( 8.560(2) 6.844(1) 15.603(3) 90.00 98.82(3) 90.00 |
Resolution range Total number of reflections | 15.42-0.85 (0.88-0.85) 10857 |
Number of unique reflections | 1588 |
Average redundancy % completeness | 6.84 (2.46) 95.7 (79.1) |
Rmerge Output <l/sigl> | 0.064 (0.118) 27.7 (7.9) |
Values in () are for the last résolution shell.
Refinement statîstics:
Final Structure Factor Calculation for example 19 in P2|
Total number of l.s. parameters = 255
GooF = S = 1.154
Weight = 1 / [ sigmaA2(FoA2) + ( 0.0421 * P )Λ2 + 0.38 * P] where P = ( Max ( FoA2, 0 ) + 2 * FcA2 ) / 3
RI = 0.0695 for 2207 Fo > 4sig(Fo)and 0.0829 for ail 2334 data, wR2 = 0.1646,
Flack x parameter = 0.09(3). χ
-9216302
Example 20 (trans - racemic mixture)
0.060 g of Example 10A were mixed with 4 mL anhydrous dioxane and 0.074 g (0.180 mmol) Lawesson’s reagent. The reaction mixture was heated to 12O°C for lh in a microwave oven. The mixture was filtered over basic alumina and eluted with DCM and MeOH. The solvents were removed under reduced pressure. The residue was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH). 22 mg of the product were obtained as sait with TFA.
HPLC-MS.· (Method l): Rt = 0.94 min
MS (ESI pos): m/z = 393 (M+H)+
Example 21 (trans - racemic mixture)
trans - racemic mixture
0.190 g (0.519 mmol) Example 8E were mixed with 1.38 mL (8.31 mmol) triethoxymethane.
The mixture was stirred for 1.5h at 150°C. The reaction mixture was allowed to cool to room
-93 16302 température and purified by préparative HPLC (eluent A: water +0.13 % TFA, eluent B: MeOH). 90 mg (46 %) of the product were obtained.
HPLC-MS (Method 1 ): Rt = 1.19 min
MS (ESI pos): m/z = 377 (M+H)+
Example 22 (trans - racemic mixture) trans - racemic mixture mg (0.10 mmol) CuCl2, 26 mL (0.22 mmol) tert-butyl-nitrite were mixed with ACN. A mixture of 22 mg (0.05 mmol) Example 12 in ACN was carefully added at 0°C. The mixture was stirred for lh at 25°C. Additional 9 mg (0.07 mmol) CuCl2 and 13 mL (0.11 mmol) tertbutyl-nitrite was added and stirred another 20 min. The solvents were removed under reduced pressure. The residue was taken up in DCM and extracted with HCl and water. The mixture was purified by préparative HPLC (eluent A: water + 0.13 % TFA, eluent B: MeOH) yieldîng2.1 mg (9 %) of the product..
HPLC-MS: (Method 3): Rt = 1.46 min
MS (ESI pos): m/z = 426/428 (Cl) (M+H)+
Example 23 (trans - racemic mixture)
-9416302
trans - racemic mixture
180 mg (0.26 mmol, content 50%, estimated by HPLC-MS) of Example 12b were mixed with 1.00 mL (6.07 mmol) 1,1,3,3-tetramethoxypropane. The reaction mixture was heated to 175°C for lh using a microwave oven. The reaction mixture was treated with DCM, washed with water. Organic layers were dried over sodiumsulphate and evaporated under reduced pressure. The crude was purified by flash cromatography (Cy/EtOAc from 80/20 to AcOEt/MeOH 96/4) and then with a second flash cromatography (DCM 100% to DCM/EtOH 96/4) to obtain the title compound as beige solid. (0.034g).
HPLC-MS (Method lEh): Rt = 6.57 min
MS (APC1 pos): m/z = 353 (M+H)+
The enantiomers of the title compound were seperated by HPLC using a chiral stationary phase.
Method for enantioseparation:
Semipreparative conditions:
HPLC semipreparative system: Waters 600 pump; column: Daicel chiralcel OJ-H, 250 mm x 20 mm, 5.0 pm; eluent: hexane/EtOH80:20; flow rate: 15 mL/min, Température: 25°C; UV Détection: 254 nm
Example | structure | Rt [min] |
-9516302
Exp. 24 trans enantiomer 1 | V ô o X | 15.604 (Method 6) |
Exp. 25 trans enantiomer 2 | V ô | 20.119 (Method 6) |
Analytical conditions
HP LC apparatus type: Agilent 1100; Method 6; column: Daicel chiralcel OJ-H, 250 mm x 4.6 mm, 5.0 pm; eluent: hexane/EtOH80:20; flow rate: 1 mL/min, Température: 25°C; UV
Détection: 254 nm
trans - racemic mixture
-9616302
140 mg (content 84%, 0.33 mmol) of Example 12C were mixed with 1.4 mL of 1,1,3,3tetramethoxypropane and L4mL of NMP. The reaction mixture was heated to 175°C for lh using a microwave oven. The reaction mixture was then diluted with MeOH and loaded on SCX cartridge. Ammonia fractions were collected and the residue was purifîed by flash 5 cromatography (Cy/EtOAc from 90/10 to 100%) to obtain the title compound as white solid (30mg).
HPLC-MS (Method lEh): Rt = 6.72 min
MS (APClpos): m/z = 370 (M+H)+
The enantiomers of the title compound were seperated by HPLC using a chiral stationary 10 phase.
Method for enantioseparation:
Semipreprative conditions:
HPLC semipreparative system: Waters 600 pump; column: Daicel chîralcel OJ-H, 250 mm x mm, 5.0 pm; eluent: hexane/EtOH80;20; flow rate: 15 mL/min, Température: 25°C; UV
Détection: 230 nm
Example | structure | Rt [min] |
Exp. 27 | b b | 17.748 |
trans enantiomer 1 | (Method 6) |
-9716302
Anal yti cal conditions
HPLC apparatus type: Agilent 1100; Method 6; column: Daicel chiralcel OJ-H, 250 mm x 4.6 mm, 5.0 pm; eluent: hexane/EtOH80:20; flow rate: 1 mL/min, Température: 25°C; UV
Détection: 254 nm
trans - racemic mixture
To a suspension of 0.132 g (0.63mmol) of 5-amino-l-(tetrahydro-pyran-4-yl)-l-H-pyrazole10 4-carboxylic acid amide (see PCT patent application WO2010/026214) in dry EtOH (1.5mL),
0.066 g (1-66 mmol) of sodium hydride (60 % suspension in minerai oil) were added at room température under nitrogen. After 10min, 0.181mg(0.945mmol) of Example 13A were added and the reaction mixture was heated to 140°C for 40 min in a microwave oven (Power 100W). The reaction mixture was then diluted with DCM, water was added, organics 15 separated and dried over sodiumsulphate. Organics were evaporated under reduced pressure
-98 16302 and the crude purified by flash cromatography (DCM/IPA 98:2) to obtain the title compound as a white solid. (54mg, 32%).
HPLC-MS (Method 1 Eh): Rt = 8.01 min
MS (APCI pos): m/z = 352 (M+H)+
The enantiomers of the title compound were seperated by HPLC using a chiral stationary phase.
Method for enantioseparation:
Semipreprative conditions:
HPLC semipreparative System: Waters 600 pump; column: Daicel chiralcel OJ-H, 250 mm x 10 20 mm, 5.0 pm; eluent: hexane/EtOH85:15; flow rate: 15 mL/min, Température: 25°C; UV
Détection: 254 nm
Example | structure | Rt [min] | ||
Exp. 30 | J | I | % | 14.754 |
NZ | ||||
trans enantiomer | Γι N | X | (Method | |
1 | O | 1 | Q | 6.1) |
Exp. 31 | J- | I | % | 16.834 |
trans enantiomer | Γι n | ( | V | (Method |
2 | 1 | A? | 6.1) | |
\=/ |
Analytical conditions z
-9916302
HPLC apparatus type: Agilent 1100; Method 6.1; column: Daicel chîralcel OJ-H, 250 mm x
4.6 mm, 5.0 pm; eluent: hexane/EtOH85:15; flow rate: 1 mL/min, Température: 25°C; UV Détection: 254 nm
Example 32 (trans - racemic mixture)
F trans - racemic mixture
To a suspension of 0.135 g (0.553 mmol) of 5-amino-l-(4,4-dîfluoro-cyclohexyl)-l-Hpyrazole-4-carboxylic acid amide (see PCT patent application W02010/026214) in dry EtOH (1.5mL), 0.066 g (1.66 mmol) of sodium hydride (60 % suspension in minerai oil) were added at room température under nitrogen. After 10min, O.lôlmg (0.837mmol) of Example 13A were added and the reaction mixture was heated to 140°C for 40 min in a microwave oven (Power 100W). The reaction mixture was then diiuted with DCM, water was added, organics separated and dried over sodium sulphate. Organics were evaporated under reduced pressure and the crude purified by flash cromatography (Cy/EA from 50:50 to 10:90) to obtain the title compound as a white solid. (54mg, 25%).
HPLC-MS (Method lEh): R, = 9.63 min
MS (APCI pos): m/z = 386 (M+H)+
The enantiomers of the title compound were seperated by HPLC using a chiral stationary phase.
Method for enantioseparation:
-10016302
Semipreprative conditions:
HPLC semipreparative System: Waters 600 pump; Column: Daicel chiralpak AD-H, 250 mm x 20 mm, 5.0 pm; eluent: hexane/Isopropanol 80:20; flow rate: 10 mL/min, Température: 25°C; UV Détection: 260 nm
Example | structure | Rt [min] | ||
Exp. 33 | ïS | 14.80 | ||
Av | ||||
trans - | il N | A | ||
/— | (Method | |||
enantiomer | \ | |||
1 | 7 | t | 7) | |
F | ||||
Exp. 34 | 20.40 | |||
AO | ||||
trans - | n | |||
—/ | /— | (Method | ||
enantiomer | ( | \ | ||
2 | 7 | ζ | 7) | |
\=/ | F |
Analytical conditions
HPLC apparatus type: Agilent 1100; Method 7; column: Daicel chiralcel AD-H, 250 mm x
4.6 mm, 5.0 pm; eluent: hexane/Isopropanol 80:20; flow rate: 1 mL/min, Température: 25°C;
UV Détection: 260 nm. /
Claims (18)
- Claimsl. A compound of formula (I) whereinR1: is a 5 or 6 membered heteroaryl-group whereby 1, 2, 3 or 4, preferably 1, 2 or 3 of the ring atoms are heteroatoms that are selected independently of each other from N, O or S, whereby said 5 or 6 membered aromatic heteroaryl-group optionally may be substituted by 1, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, HO-, NC-, F3C-, HF;C-, FIfC- methyl, IFN- and (CH3)2N-;R : is selected from the group consisting of fluorine, NC-, F3C-, HF2C-, FH2C- and methyl, preferably fluorine, NC-, F3C- and methyl;D: is selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, 2-, 3- and 4-pyridyl, whereby cyclopentyl and cyclohexyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another fforn the group consisting of fluorine, NC-, F3C-, HF2C- and FH2C-;whereby tetrahydrofuranyl and tetrahydronvranyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, NC-, F3C-, HF2C- and FH2C- ;whereby pyridyl optionally may be substituted by 1, 2, 3 or 4 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C-, F3C-CH2-, Ci.6-alkyl- and C3_7-cycloalkyl, m: is selected from 1 or 2, preferably m is 1 ;n: is selected from 0, 1 or 2, preferably n is 0 or 1, more preferably n is 0, whereby if n = 2, these two groups R are selected independently of one another;- 10216302 and salts, preferably pharmaceutically acceptable salts thereof;with the proviso that the compound is not mixture of ail or some thereof.be it in the form of any possible stereoisomer or a
- 2. A compound according to claim 1, whereinR1: is a 5 or 6 membered heteroaryl-group whereby 1, 2, 3 or 4 preferably 1, 2 or 3 of the ring atoms are heteroatoms that are selected independently of each other from N, O or S, whereby said 5 or 6 membered aromatic heteroaryl-group optionally may be substituted by 1, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C-, methyl, H2N- and (CH3)2N-;R2: is selected from the group consisting of fluorine, NC-, F3C-, HF2C-, FH2C- and methyl, preferably fluorine, NC-, F3C- and methyl;D: is selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl 2-, 3- and 4-pyridyl, whereby cyclopentyl and cyclohexyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- and FH2C-;whereby tetrahydrofuranyl and tetrahydropyranyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- and FH2C- ;- 103 16302 whereby pyridyl optionally may be substituted by l, 2, 3 or 4 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C- F3C-CH2-, Ci_6-alkyl- and Cv.-cycloalkyl.m: îs selected from l or 2, preferably m is 1 ;n: is selected from 0, 1 or 2, preferably n is 0 or 1, more preferably n îs 0, whereby if n 2. these two groups R are selected independently of one another;and salts, preferably pharmaceutically acceptable salts thereof;with the proviso that the compound is not mixture of ail or some thereof be it in the form of any possible stereoisomer or a
- 3. A compound according to claim 2, whereinR': îs a heteroaryl-group selected from the group consisting of thiadiazolyl, oxadiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyridyl and pyrimidinyl, whereby said heteroaryl-group optionally may be substituted by 1, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C- methyl, H2N- and (CH3)2N-.
- 4. A compound according to claim 1, wherein /- 10416302R1: is a heteroaryl-group selected from the group consîsting of thiadiazolyl, 1,2,3oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyridyl and pyrimidînyl, preferably said group consîsting of thiadiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyridyl and pyrimidinyl, whereby said heteroaryl-group optionally may be substituted by 1, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consîsting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C-, methyl, H2N- and (CH3)2N-;R2: is selected from the group consîsting of fluorine, NC-, F3C-, HF2C-, FH2C- and methyl, preferably fluorine, NC-, F3C- and methyl;D: is selected from the group consîsting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, 2-, 3- and 4-pyridyl, whereby cyclopentyl and cyclohexyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consîsting of fluorine, F3C-, HF2C- and FH2C-;whereby tetrahydrofuranyl and tetrahydropyranyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consîsting of fluorine, F3C-, HF2C- and FH2C- ;whereby pyridyl optionally may be substituted by 1, 2, 3 or 4, preferably 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consîsting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2CF3C-CH2-, Ct 6-alkyl- and C3.7-cycloalkyl.m: is selected from 1 or 2, preferably m is 1 ;n: is selected from 0, 1 or 2, preferably n is 0 or 1, more preferably n is 0, whereby if n = 2, these two groups R2 are selected independently of one another;and salts, preferably pharmaceutically acceptable salts thereof.
- 5. A compound according to any of ciaims 1 to 4, whereby R1 is no oxadiazolyl, neither unsubstituted nor substituted.
- 6. A compound according to claim 4, wherein /- 10516302Rl: is a heteroaryl-group selected from the group consisting of [l,3.4]thiadiazol-2-yl, isoxazol-5-yl, thiazol-5-yl-, oxazol-2-yl, pyridin-2-yl and pyrimidin-2-yl, whereby said heteroaryl-group optionally may be substituted by l or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, CN-, methyl and H2N-;R2: is selected from the group consisting of fluorine, NC-, F3C-, HF2C-, FH2C- and methyl, preferably fluorine, NC-, F3C- and methyl;D: is selected from the group consisting of cyclopentyl, cyclohexyl, tetrahydrofuranyl, thereof preferably tetrahydrofuran-3yl, tetrahydropyranyl, thereof preferably tetrahydropyran4yl, 2-, 3- and 4-pyridyI, whereby cyclopentyl and cyclohexyl optionally may be substituted by l or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- and FH2C-; preferably fluorine;whereby tetrahydrofuranyl and tetrahydropyranyl optionally may be substituted by 1 or 2 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, F3C-, HF2C- and FH2C- ;whereby pyridyl optionally may be substituted by 1, 2, 3 or 4 substituents, whereby said substituents may be selected independently of one another from the group consisting of fluorine, chlorine, bromine, NC-, F3C-, HF2C-, FH2C- F3C-CH2- and methyl;whereby preferably D is selected from the group of 4,4-dîfluorocyclohex-l-yl, tetrahydropyranyl, preferably tetrahydropyran-4-yl, and 4-methy-3-pyridyl;m: is selected from 1 or 2, preferably m is 1 ;n: is selected from 0, 1 or 2, preferably n is 0 or 1, more preferably n is 0, whereby if n = 2, these two groups R are selected independently of one another;and salts, preferably pharmaceutically acceptable salts thereof.
- 7. A compound according to claim 1, characterised in that it is a compound according to formula (II)- 10616302 (il), whereinR1 : is as defined in any of claims 1, 2, 3,4, 5 or 6;5 D: is selected from the group consisting of 4,4-difluorocyclohexyl, tetrahydropyran-4-yl and4-methy-3-pyridyl whereby neither 4,4-difluorocyclohexyl nor tetrahydropyran-4-yl has additional substituents;and salts, preferably pharmaceutically acceptable salts thereof.
- 8. A compound according to claim 7, wherein the compound is selected from the group- 10716302- 108 16302- 10916302-no16302- Ill 16302- U216302- 11316302- Il416302- 115 16302-11616302- 117 16302- us16302-11916302 and salts, preferably pharmaceutically acceptable salts thereof.- 120 16302
- 9. A compound according to any one of claims l-6, whereby the compound îs selected from the group of a compound according to formula (la), formula (Ib), formula (le) and formula (Id) (la), (le), (Id), with R1, R2, D, n and m as defined or presented in any of claims l to 65 and salts, preferably pharmaceutically acceptable salts thereof.
- 10. A compound according to any one of claims 7 and 8, whereby the compound is selected from the group of a compound according to formula (Ha), formula (Ilb), formula (lie) and formula (Ild) (Ha), (Hb), (Ile), (Ild), with R1 and D as defined in any of claims 7 to 8 /- 121 16302 and salts, preferably pharmaceutically acceptable salts thereof.
- 11. A compound according to any one of daims 1 to 10 for use as a médicament or for the use as pharmaceutically active ingrédient in a médicament, preferably a médicament for use in a therapeutic or prophylactic method, preferably in a therapeutic method.
- 12. A compound according to any one of daims 1 to 10 for use in a therapeutic or prophylactic, preferably a therapeutic method (a) for the treatment of a CNS disease, more preferably a CNS disease, the treatment of which is accessible by the inhibition of PDE9, (b) for the treatment of a disease that is accessible by the inhibition of PDE9, (c) for the treatment of or for the amelioration of or for the prévention of, preferably for the treatment of a condition being selected from the group consisting of cognitive impairment being related to a disease or condition selected from the group of perception, concentration, cognition, leaming or memory, whereby preferably the treatment, amelioration or prévention of cognitive impairment is related to ageassociated leaming and memory impairments, age-associated memory losses, vascular dementia, craniocerebral trauma, stroke, dementia occurring after strokes (post stroke dementia), post-traumatic dementia, general concentration impairments, concentration impairments in children with leaming and memory problems, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes, including Pîck's syndrome, Parkinson’s disease, progressive nuclear palsy, dementia with cortîcobasal degeneration, amyotropic latéral sclerosis (ALS), Huntîngton's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia, epîlepsy, temporal lobe epilepsy, schizophrenia, schîzophrenia (with dementia), Korsakoff s psychosis or cognitive impairment associated with dépréssion or bîpolar disorder, (d) for the treatment of Alzheimer’s disease or cognitive impairment associated with Alzheimer’s disease, x- 12216302 (e) for the treatment of schizophrenia or cognitive impairment associated with schizophrenia, (f) for the treatment of epilepsy or cognitive impairment associated with epilepsy, (g) for the treatment of a disease or condition being selected from the group consisting of sleep disorders, bipolar disorder, metabolic syndrome, obesity, diabètes mellitus, hyperglycemia, dyslipidemia, impaired glucose tolérance, or a disease of the testes, brain, small intestine, skeletal muscle, heart, lung, thymus or spleen.
- 13. A compound according to any one of claims 1 to 10 for use în a method for the treatment or prophylaxis of cognitive impairment, préférable cognitive impairment related to perception, concentration, leaming or memory.
- 14. A compound according to any one of claims 1 to 10 for use in a method for the treatment or prophylaxis of cognitive impairment, préférable cognitive impairment related to perception, concentration, leaming or memory, as symptoms of anther base laying disease.
- 15. A compound according to any one of claims 1 to 10 for use in a method for the improvement of cognitive skills related to perception, concentration, leaming or memory.
- 16. Pharmaceutical composition comprising a compound according to any one of claims 1 to 10 and a pharmaceutical carrier.
- 17. Use of a compound according to any one of claims 1 to 10 for the manufacture of a médicament for the treatment of a disease or condition as defined în any of claims 12 to 15.
- 18. Combination of a compound according to any one of claims 1 to 10 with another active agent, whereby /- 123 16302- said combination preferably îs useful for the treatment of a disease or condition as defined in any of claims 12 to 15 or- said combination preferably being for the use in a therapeutic or prophylactic method, preferably a therapeutic method, for the treatment of a condition or disease as defined in any5 of claims 12 to 15 or- said combination being for the manufacture of a médicament which preferably is for the treatment of a condition or disease as defined in any of claims 12 to 15. —
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10172597.6 | 2010-08-12 | ||
EP11154397.1 | 2011-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16302A true OA16302A (en) | 2015-04-24 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2603511B1 (en) | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors | |
EP2675807B1 (en) | 6-cyclobutyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors | |
US8809345B2 (en) | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | |
WO2010112437A1 (en) | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators | |
OA16302A (en) | 6-Cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors. | |
OA16512A (en) | 6-cyclobutyl-1,5-dihydro-pyrazolo[3,4D]pyrimidin-4-one derivatives and their use as PDE9A inhibitors. |